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ABSTRACT OF THESIS 
 
 
EXTENSIVELY DRUG-RESISTANT PSEUDOMONAS AERUGINOSA IN VITRO 
SUSCEPTIBILITY AND MECHANISMS OF RESISTANCE 
 
 
Pseudomonas aeruginosa causes severe healthcare-associated infections. Forty-
eight extensively drug-resistant (XDR)-P. aeruginosa isolates were selected from 287 
isolates collected for evaluation based on clinical susceptibility data. In vitro activity of 
commonly utilized antimicrobials (i.e. antipseudomonal beta-lactams, aminoglycosides, 
fluoroquinolones, and polymyxins) plus ceftolozane-tazobactam, ceftazidime-avibactam, 
and aztreonam-avibactam against XDR-P. aeruginosa were determined. The mechanism 
of resistance profile was determined through phenotypic expression analysis. Overall, 
polymyxin B and colistin were 100% susceptible. Apart from the polymyxins, 
ceftolozane-tazobactam had the highest susceptibility (94%) followed by ceftazidime-
avibactam (90%) and amikacin (83%). Ceftolozane-tazobactam activity was not 
significantly different from ceftazidime-avibactam (p=0.6831). Only 40% of isolates 
were susceptible to aztreonam-avibactam. All other agents demonstrated <8% 
susceptibility. Not surprisingly, AmpC expression was the most common mechanism of 
resistance (96%) followed by OprD porin channel downregulation and efflux pump 
system expression at 85% and 83%, respectively. Most isolates (73%) expressed at least 
three mechanisms of resistance. The most common combination was AmpC, OprD 
downregulation, and efflux pump expression. This combination as well as its high 
susceptibility and potency suggests preferential use of ceftolozane-tazobactam. For XDR-
P. aeruginosa at our institution, in vitro analysis proposes superiority of ceftolozane-
tazobactam; however, until further in vitro and in vivo validation both agents are 
reasonable options. 
 
KEYWORDS: Extensively drug-resistant, Pseudomonas aeruginosa, ceftolozane-
tazobactam, ceftazidime-avibactam, aztreonam-avibactam, mechanisms 
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CHAPTER 1.  INTRODUCTION 
1.1 EPIDEMIOLOGY 
It has been estimated that by the year 2050 there will be ten million deaths 
annually worldwide due to antimicrobial resistance. This estimate is greater than the 
annual prediction of 8.2 million deaths worldwide due to cancer(1). In 2019, the Centers 
for Disease Control and Prevention updated the Antibiotic Resistance Threat Report. The 
new national estimates include nearly three million infections annually caused by all 
antimicrobial resistant bacteria and fungi causing 35,900 deaths(2). Overall, data is 
limited for P. aeruginosa because global surveillance, epidemiological characterization, 
and resistance pattern development is particularly difficult in this organism due to the 
diverse mechanisms of resistance acquired and utilized by P. aeruginosa. Multidrug-
resistant (MDR) P. aeruginosa continue to cause a variety of healthcare-associated 
infections such as pneumonia, urinary tract infections, bloodstream infections, and 
surgical site infections(2). P. aeruginosa is considered the sixth most common pathogen 
in healthcare-associated infections, and the second most common cause of healthcare-
associated pneumonia(3). Even though the prevalence of MDR-P. aeruginosa causing 
infections in hospitalized infections has decreased considerably in the United States since 
2012, the organism is still considered a serious threat. There were an estimated 46,000 
cases of MDR-P. aeruginosa in 2012, 36,200 cases in 2016, and 32,600 cases of MDR-P. 
aeruginosa in hospitalized patients in 2017. Of the 32,600 cases, there were an estimated 
2,700 deaths and a $767 million attributable healthcare cost(2). The Centers for Disease 
Control and Prevention have illustrated the public health concern created by this 
organism. The World Health Organization has also illustrated the concern through a 
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different approach. They have similarly released a ranking of the most critical or 
worrisome resistant organisms. However, they focused on research and development 
initiatives rather than the public health burden of disease. Their ranking considers 
carbapenem-resistant P. aeruginosa the highest priority, second only to carbapenem-
resistant Acinetobacter baumannii, for pursuing research and development of new 
antimicrobial agents against these threatening organisms(4).  
Both the Centers for Disease Control and Prevention and the World Health 
Organization highlight a need to investigate these organisms further, but their 
terminology and categorization needs to first be understood. The Centers for Disease 
Control and Prevention depicted the concern of MDR-P. aeruginosa while the World 
Health Organization focused on carbapenem-resistant P. aeruginosa. These are not one in 
the same as carbapenem resistance only focuses on one category of antipseudomonal 
agents. Since P. aeruginosa is intrinsically resistant to many antimicrobial agents such as 
tetracyclines, trimethoprim-sulfamethoxazole, and many beta-lactams, there are only 
seven antipseudomonal categories considered treatment options for P. aeruginosa. These 
include cephalosporins, beta-lactam/beta-lactamase inhibitors, monobactams, 
carbapenems, aminoglycosides, fluoroquinolones, and polymyxins(5). Only agents active 
against P. aeruginosa can be considered when determining the pathogen’s level of 
resistance. A P. aeruginosa isolate is deemed multidrug-resistant if it is non-susceptible 
to at least one agent from at least three antipseudomonal categories(6). Therefore, 
organisms included in the Centers for Disease Control and Prevention’s analysis may or 
may not have carbapenem-resistance.  The Centers for Disease Control and Prevention 
and the World Health Organization provide the foundation for why various levels of non-
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susceptible organisms need attention, but they do not address an even more concerning, 
more resistant subpopulation of P. aeruginosa. Isolates that are extensively drug-
resistant. A microbial organism is considered extensively drug-resistant (XDR) if it is 
non-susceptible to at least one agent from all but two or less of the antipseudomonal 
categories(6). Organisms at our institution considered extensively drug-resistant are of 
highest interest.  
The International Network for Optimal Resistance Monitoring (INFORM) group 
has evaluated XDR-P. aeruginosa. Their surveillance studies suggest why XDR-P. 
aeruginosa are even more concerning than MDR-P. aeruginosa or carbapenem-resistant 
P. aeruginosa and are of highest interest at our institution. They evaluated isolates across 
79 medical centers in the United States as well as centers in other countries including 
Spain, Thailand, Greece, and Iran. They have determined that 9% of all isolates in the 
United States have exhibited an XDR phenotype. Overall, the prevalence of the XDR 
phenotype in the United States was less than the prevalence found through epidemiologic 
studies in these other countries. The XDR phenotype prevalence in Spain was 11%, 
Thailand 22%, Greece 25%, and Iran 33%. Further, the INFORM group also found the 
prevalence of the XDR phenotype in various patient populations in addition to the 
geographic populations. Burn patients and solid organ transplant patients were found to 
have a high prevalence of the XDR phenotype(5). P. aeruginosa is considered one of the 
most common pathogens involved in nosocomial infections of burn patients(7). A single 
center study in Iran found that 87% of burn patients with P. aeruginosa wound infections 
had an XDR phenotype(5,7). While our institution is not a burn center, it does perform 
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numerous solid organ transplantations including heart, lung, kidney, pancreas, and liver 
transplants.  
A single center study from 2007 to 2013 in Spain found that 63% of solid organ 
transplant patients with P. aeruginosa bacteremia had an XDR phenotype(5,8). 
Transplantations included heart, liver, and kidney transplants. The median time from 
organ transplantation to bacteremia was significantly shorter in the XDR phenotype 
group, 66 days vs 278 days (p=0.03)(8). Significantly more patients with the XDR 
phenotype presented with shock compared to other etiologies, 43.3% vs 15.5% 
(p=0.001). Patients’ infections were not only more critical at presentation and the 
infection more rapidly spread in the XDR phenotype, but patients with the XDR 
phenotype compared to other etiologies were also more likely to have received 
inappropriate empiric therapy (58% vs 22%, p<0.001); more frequently had persistence 
of infection (20.7% vs 7.7%, p=0.03), respiratory failure (36.7% vs 13%, p=0.002), and 
intensive care unit admission (58.1% vs 24.8%, p<0.001); and an overall higher mortality 
rate within the first 7 days (20.7% vs 8.5%, p=0.04) and 30 days (38% vs 16%, p=0.009) 
of onset of bacteremia. Of the patients with an XDR phenotype who received 
inappropriate empiric therapy, 50% died of septic shock(8). Finally, risk factors for a P. 
aeruginosa infection with an XDR phenotype included receipt of parenteral nutrition, 
prior fluoroquinolone use, prior carbapenem use, hematological malignancy, mechanical 
ventilation, and higher Acute Physiology and Chronic Health Evaluation (APACHE II) 
scores(5,9). Overall, the burden of increasing resistance of P. aeruginosa worldwide is of 
concern, and it is imperative for optimal antimicrobial use. Prior antimicrobial exposure 
was shown to be a risk factor for the XDR phenotype, and inappropriate empiric therapy 
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led to worse outcomes. The XDR-P. aeruginosa population at our institution needs to be 
better characterized and understood in order to prevent inappropriate empiric therapy 
decision-making that leads to worse patient outcomes.  
The Centers for Disease Control and Prevention, World Health Organization, and 
INFORM group all holistically demonstrated the global problem, but as mentioned P. 
aeruginosa are very diverse and have high inter-institutional variability. Before measures 
at our institution can be taken to combat this problem, the population of P. aeruginosa at 
University of Kentucky HealthCare needs to be characterized and well understood 
starting with its epidemiology. Over the past ten years from 2000 to 2019 the University 
of Kentucky HealthCare has seen about 5000 P. aeruginosa isolates, about 500 isolates 
each year. Overall, there has been minimal change from year to year in incidence of 
infection and susceptibility patterns. The most common source was respiratory at 40% of 
cultures, then urine cultures at 20%, and skin and soft tissue cultures at 20%. Blood 
cultures only sourced 7-10% of all isolates. About 54% of all P. aeruginosa isolates were 
susceptible to all antipseudomonal categories, 20% were MDR-P. aeruginosa, and 7% 
considered XDR-P. aeruginosa. This 7% of isolates is similar to the national surveillance 
data from INFORM showing 9% of all P. aeruginosa isolates in the United States had an 
XDR phenotype. Finally, about 20% of isolates were meropenem-resistant. Of these 
isolates, 20% were also resistant to all other beta-lactams tested. These included 
cefepime, piperacillin-tazobactam, and aztreonam. This epidemiologic data is derived 
from BD Phoenix™ Automated Systems susceptibility panel results. The activity of the 
new beta-lactam/beta-lactamase inhibitor antimicrobials against any of these isolates is 
still unknown. Further, these new agents target different mechanisms of resistance, and 
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the resistance patterns at our institution are also unknown. Having an understanding of 
what mechanisms of resistance are at play allows for choosing more optimal therapy up 
front when an agent is considered prior to any susceptibility results. In order to 
understand the impact of both determining the mechanisms of resistance pattern of our 
population of XDR-P. aeruginosa and then the activity of the new agents against these 
complicated organisms, a discussion on what is already known about the various 
mechanisms of resistance utilized by P. aeruginosa and the new antipseudomonal beta-
lactam/beta-lactamase inhibitors is needed.     
1.2  MECHANISMS OF RESISTANCE 
There are four classes of mechanisms of resistance utilized by microbial 
organisms. These include efflux pump system production, decreased permeability to 
antimicrobial agents through decreased porin channel production, enzyme production for 
antimicrobial degradation, and antimicrobial target site alteration. XDR-P. aeruginosa 
have limited antimicrobial therapeutic options because they acquire and utilize all four 
mechanisms of resistance in various patterns and have a high level of inherent resistance 
(Figure 1)(5). There are many families of efflux transporter systems in bacteria including 
resistance-nodulation-division superfamily (RND), major facilitator superfamily (MFS), 
multidrug and toxic compound extrusion (MATE), small multidrug resistance (SMR), 
and ATP-binding cassette superfamily (ABC)(10). P. aeruginosa have highly efficient 
RND efflux systems, with at least twelve different types of systems characterized. 
Involvement of the other efflux pump system families is limited in P. aeruginosa. RND 
pumps sit on the inner membrane of the cell and then interact with a periplasmic adaptor 
protein, or membrane fusion protein, and outer membrane channel creating a tripartite 
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complex. This complex allows drugs to be directly expelled into the external medium and 
causes slowed drug reentry through the outer membrane. This configuration is very 
efficient compared to other efflux systems in creating antimicrobial resistance(10). The 
MexAB-OprM pump was the first RND efflux system characterized in P. aeruginosa. 
Substrate specificity of MexAB-OprM encompasses a wide spectrum of antimicrobial 
agents with varying structures. These include antipseudomonal cephalosporins such as 
ceftazidime, fluoroquinolones, carbapenems except imipenem, and 
aminoglycosides(5,10–12). When there are genetic mutations that result in the 
overexpression of the MexAB-OprM system by at least 3-fold, there is a 2- to 16-fold 
increase in MIC of all pump antimicrobial substrates(10). This system is prevalent among 
resistant populations with a rate of about 50% of non-cystic fibrosis isolates being 
MexAB-OprM overproducers.  
 
 
Figure 1: Mechanisms of Resistance of XDR-P. aeruginosa 
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Other RND efflux systems utilized by P. aeruginosa and that have a known 
clinical relevance include MexXY-OprM, MexCD-OprJ, and MexEF-OprN. Substrates 
of MexXY-OprM include aminoglycosides, fluoroquinolones, and cefepime. 
Overexpression of MexXY-OprM causes a 2- to 16-fold increase in MIC of all 
antimicrobial substrates. MexCD-OprJ is not expressed in wild-type strains but is usually 
an inducible efflux system. When MexCD-OprJ is induced and overexpressed there is 
resistance to fluoroquinolones and cefepime. However, it also causes a hypersensitivity to 
other beta-lactams and aminoglycosides because its overexpression results in decreased 
production of MexAB-OprM and impaired inducibility of the AmpC-beta-lactamase. 
This means that while an isolate becomes resistant to levofloxacin, for example, it may 
also then become more susceptible to meropenem or ceftazidime. Finally, the only 
antipseudomonal substrates of MexEF-OprN are fluoroquinolones. The 2015 Clinical 
Microbiology Review is a great discussion of efflux pump systems utilized by gram 
negative organisms and should be referenced for more information about each of these 
systems(10). 
In order to detect expression of these RND efflux systems commonly utilized by 
P. aeruginosa and better understand what mechanisms of resistance are causing the high-
level of resistance seen in our XDR-P. aeruginosa, the phenotypic effect of efflux pump 
inhibitors can be assessed. Phenylalanine-arginine 𝝱-naphthylamide (PA𝝱N), also 
referred to as MC-207, 110, is a broad-spectrum efflux pump inhibitor discovered in 
2001. It is the inhibitor of choice for efflux pump detection in our population of P. 
aeruginosa because it was found to inhibit MexAB-OprM, MexCD-OprJ, and MexEF-
OprN; three of the four common RND efflux systems utilized by P. aeruginosa discussed 
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above(10,13). When the efflux pump inhibitor is combined with an antimicrobial agent 
that is a substrate of the RND pumps, the in vitro activity of the antimicrobial agent 
should change if the pump is present. If the pump is expressed or overexpressed by the P. 
aeruginosa cell, when inhibited by PA𝝱N, the MIC of the antimicrobial agent should 
decrease because more of the agent is able to stay active at its site of action inside the cell 
and a smaller total antimicrobial agent concentration is needed to have the same killing 
effect. When testing XDR-P. aeruginosa isolates from our institution multiple 
antimicrobial substrates will be tested to verify results because each pump favors some 
agents more than others and the inhibitor and antimicrobial agents have different binding 
sites on the efflux pump. There may be variations in the effect inhibition of the efflux 
system has on the in vitro activity of the antimicrobial agent. If the MIC of either agent, 
cefepime or meropenem, decreases at least 2-fold when combined with PAβN then the 
XDR-P. aeruginosa isolate can be considered positive for utilizing one of the efflux 
pump systems to create resistance(10,14,15).    
P. aeruginosa are unique because they not only utilize various efflux pump 
systems to create resistance, but also manipulate their porin channel systems to prevent 
entry of an antimicrobial agent and become resistant. When porin channels are present, 
compounds, including antimicrobial agents, can more readily and rapidly enter the cell. It 
is much slower and more difficult for a bulky, charged, or polar substance to diffuse 
across the cell membrane. P. aeruginosa overall have very low permeability. Porin 
channels commonly utilized by P. aeruginosa include OprB and OprD. OprB channels 
are specific for glucose uptake while OprD channels are responsible for the uptake of 
basic amino acids and peptides. Even though these channels are intended for intake of 
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essential nutrients, they can also transport antimicrobial agents. The OprD porin channel 
is the primary channel for entry of carbapenems into the cell(10). When this channel is 
downregulated, the organism becomes resistant to imipenem and has reduced 
susceptibility to meropenem. When there is MexAB-OprM efflux system overexpression 
in combination with inactivation of OprD porin channel there is increased resistance. The 
organism becomes resistant to both imipenem and meropenem(5,11). This combination is 
one of the major causes of meropenem resistance(12). This is of interest because 
carbapenems are the backbone of treatment options for resistant organisms, and as the 
World Health Organization recognized combating carbapenem resistance is of highest 
priority(4). Prior to the development of these new beta-lactam/beta-lactamase inhibitors 
they were the last resort treatment options. Once an organism became resistant to 
carbapenems, the remaining available treatment options were minimal to zero.  
It is important to determine if our carbapenem-resistant XDR-P. aeruginosa are 
non-susceptible to carbapenems because of this interplay of porin channel 
downregulation and efflux pump upregulation. Which mechanisms are utilized impacts 
which new agent is recommended as the empiric treatment of choice. PAβN is the 
inhibitor of choice to detect the presence of efflux pump systems, and similarly an 
inhibitor of OprD porin channels will be tested to detect the presence of porin channel 
inactivation. L-arginine is a basic amino acid and a known substrate of OprD porin 
channels. When L-arginine is combined with a carbapenem, the carbapenem’s in vitro 
activity may change depending on the presence of the channel. If the XDR-P. aeruginosa 
isolate has stopped production of OprD porin channels in order to prevent the entry of 
unwanted substances such as carbapenems, then L-arginine should have no effect on the 
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MIC of the carbapenem. There are no channels present for L-arginine to utilize and 
consequently block. If the XDR-P. aeruginosa isolate is producing OprD porin channels 
normally, utilizing a different mechanism of carbapenem resistance, and allowing 
substances such as L-arginine or a carbapenem to enter the cell, then the activity of the 
carbapenem should decrease in the presence of L-arginine. As a substrate of the channel 
it acts as a competitive inhibitor of carbapenems. L-arginine’s binding and utilization of 
the channel prevents the carbapenem from entering the cell and reaching its site of action. 
Both efflux pump systems and porin channel regulation are critical components of P. 
aeruginosa defense strategies and characterizing the use of these mechanisms by our 
population to develop a resistance patten will be valuable in determining treatment plans 
when options are limited.      
There is also an abundance of deactivating enzymes both inherently produced by 
P. aeruginosa and acquired through plasmid transfer that create high levels of 
antimicrobial resistance. The production of beta-lactamases has mirrored the progression 
of antibiotic development overtime due in part to survival of the fittest and natural 
selection. First, penicillin agents were developed and then organisms with the ability to 
upregulate production of penicillinase enzymes were selected and survived. To overcome 
penicillin resistance cephalosporins and beta-lactamase inhibitors were created, and then 
shortly following cephalosporinases expressed and produced by organisms. Finally, 
carbapenems were brought to market and then carbapenemases overexpressed (Figure 
2)(16). This is the point in the sequence when research and development of antimicrobial 
agents plateaued, came to a near halt, and there was nothing to treat these now 
carbapenem resistant organisms due to carbapenemase activity. Then, the new beta-
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lactam/beta-lactamase inhibitors were finally developed and able to overcome some of 
these carbapenemases. As will be further discussed, the new agents do not target the same 
enzymes, so again it is imperative to have an understanding of an institution’s resistance 
patterns in order to select the most appropriate empiric therapy and improve patient 
outcomes. As previously mentioned, 50% of solid organ transplant patients with an XDR-
phenotype given inappropriate empiric therapy died of septic shock(8). Selecting the 
wrong agent can be detrimental. 
 
 
 
Figure 2: Evolution of Beta-Lactamases  
(ESBL=extended spectrum beta-lactamase; KPC=Klebsiella pneumoniae carbapenemase; 
MBL=metallo-beta-lactamase; TEM-1, TEM-2, SHV-1, TEM, SHV, CTX-M=types of 
beta-lactamases) 
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Overall, there are four classes of beta-lactamase enzymes. Class A beta-
lactamases are considered the serine-beta-lactamases and include TEM, SHV, and 
Klebsiella pneumoniae carbapenamase (KPC). Class B beta-lactamases are the metallo-
beta-lactamase (MBL) carbapenamases including VIM, IMP, and NDM. Class C beta-
lactamases includes the AmpC cephalosporinase. Class D beta-lactamases are the 
oxacillinases (OXA)(17). P. aeruginosa intrinsically possess the AmpC gene 
chromosomally. Mutations can occur that cause hyper-inducible AmpC production 
leading to resistance to penicillins, cephalosporins, and monobactams(5). Further, when 
AmpC hyperproduction occurs in combination with either an efflux pump expression or 
porin channel downregulation discussed above, carbapenem resistance results(18). If this 
combination of mechanisms is causing carbapenem resistance, then ceftolozane-
tazobactam might be the preferred empiric agent compared to ceftazidime-avibactam 
because of the mechanisms they target. Ceftolozane-tazobactam is more active against 
efflux systems, AmpC production, and porin channel downregulation while ceftazidime-
avibactam is active against serine carbapenemases such as KPC. The KPC enzyme is 
encoded by the blaKPC gene found on the transposon and readily able to insert into 
plasmid DNA for transfer between bacteria. It is more commonly found in carbapenem 
resistant Enterobacteriaceae such as K. pneumoniae, compared to P. aeruginosa(19). 
Both AmpC and KPC enzymes degrade antibiotic agents through a hydrolysis process in 
which a serine side chain within the enzyme active site creates an acyl-enzyme 
intermediate prior to the opening of the beta-lactam ring and ultimate destruction(20). 
MBL carbapenemases on the other hand utilize a zinc cation in the active site to initiate 
the hydrolytic process and destruction of the beta-lactam ring(21). MBLs are the most 
14 
 
common carbapenemases in P. aeruginosa, with the VIM and IMP subtypes being the 
most frequent and geographically widespread(12). Monobactams such as aztreonam are 
the only beta lactam agents protected against MBL enzyme degradation. Neither 
ceftolozane-tazobactm nor ceftazidime-avibactam are active against MBL 
carbapenemases. Finally, MBL enzymes are plasmid-borne, meaning their encoded 
genetic material is mobile and able to be horizontally transferred not only amongst 
similar species but also unrelated bacteria(21).  
Similar to efflux pump expression and porin channel downregulation, inactivating 
enzyme production can be detected through the use of enzyme inhibitors. Enzymes tested 
include AmpC-beta-lactamase, KPC, and MBL carbapenemase. AmpC-beta-lactamases 
and KPC can both be detected through assessing the change in killing when combined 
with phenylboronic acid (PBA)(22). The XDR-P. aeruginosa isolate should become 
more susceptible to imipenem in the presence of PBA because it is preventing the 
enzyme from degrading the antimicrobial agent and allowing it to reach its target site. In 
order to differentiate between KPC and AmpC production, the activity of the 
antimicrobial agents imipenem and meropenem was assessed in the presence of 
cloxacillin. Cloxacillin is also a known inhibitor of AmpC-beta-lactamase. If the MIC of 
imipenem or meropenem decreases at least 2-fold when combined with cloxacillin then 
the isolate can be considered positive for AmpC-beta-lactamase production(14). Isolates 
considered positive for AmpC or KPC production when combined with PBA and positive 
for AmpC production when combined with cloxacillin are considered AmpC positive. 
Isolates considered positive for AmpC or KPC production when combined with PBA and 
negative for AmpC production when combined with cloxacillin are considered KPC 
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positive. Isolates are not considered positive for both AmpC and KPC production. 
Finally, EDTA is an inhibitor of MBL carbapenemases(23). The susceptibility to 
imipenem should improve in the presence of EDTA if the XDR-P. aeruginosa isolate is 
positive for MBL production.   
XDR-P. aeruginosa can utilize RND efflux transport pump systems such as the 
MexAB-OprM system, stop production of porin channels like OprD, and produce 
enzymes such as AmpC beta-lactamases to become resistant to almost all antimicrobial 
agents, particularly carbapenems. Carbapenems were considered the last line of defense.  
As the global burden of antimicrobial resistance increases to a point that surpasses cancer 
and P. aeruginosa become more diverse and remain difficult to globally characterize, it is 
imperative for each institution to create at least a baseline description of their population. 
Institutions cannot completely depend on the limited surveillance data to make 
therapeutic decisions. This will allow for more appropriate use of new agents such as 
ceftazidime-avibactam, ceftolozane-tazobactam, and aztreonam-avibactam (not FDA 
approved). 
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1.3 CEFTAZIDIME-AVIBACTAM 
Approved in 2015, ceftazidime-avibactam is one of the new beta-lactam/beta-
lactamase inhibitor combinations specifically of interest against P. aeruginosa infections. 
In patients 18 years and older it has approval for complicated intra-abdominal infections, 
complicated urinary tract infections including pyelonephritis, and hospital-acquired 
bacterial pneumonia and ventilator-associated bacterial pneumonia caused by P. 
aeruginosa(24). While ceftazidime is an older third-generation cephalosporin, avibactam 
is a novel diazabicyclooctane beta-lactamase inhibitor. Avibactam is a non-beta-lactam 
beta-lactamase inhibitor.  It contains a five-membered cyclic urea instead of the four-
membered beta-lactam ring(25). Avibactam covalently and reversibly binds to serine 
beta-lactamases; therefore, it has potent activity against KPC and AmpC beta-lactamases 
but does not have activity against MBL carbapenemases(26). Avibactam is most potent 
against Class A and Class C beta-lactamases, but has weaker inhibition against Class D 
beta-lactamases(25). The mechanism of action of avibactam differs from other beta-
lactamase inhibitors in that it does not serve as the enzyme substrate and bind 
irreversibly, but instead reversibly binds to the enzyme causing a slowed deacylation and 
ring closure. This allows avibactam to regain activity and cause inhibition to other 
enzymes. This reversion is most likely due to the lesser intrinsic strain of a five-
membered ring than a four-membered ring(25). 
Addition of avibactam was shown to effectively lower MICs and improve 
susceptibility to ceftazidime in P. aeruginosa, MDR-P. aeruginosa, and XDR-P. 
aeruginosa(27,28). One of the early studies investigated the in vitro activity of 
ceftazidime-avibactam in 126 P. aeruginosa isolates from a hospital in France between 
December 2006 and April 2007. Sixty-five percent of the isolates were susceptible to 
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ceftazidime alone, 86% were susceptible to imipenem, and 94% susceptible to 
ceftazidime-avibactam. The MIC50 and MIC90 of ceftazidime alone were 8 µg/ml and 64 
µg/ml, respectively. The MIC50 and MIC90 of ceftazidime-avibactam were 4/4 µg/ml and 
8/4 µg/ml, respectively(28). Following this study, a larger surveillance study investigated 
the in vitro activity of 3,902 P. aeruginosa isolates from 75 medical centers in the United 
States isolated between January 2012 and December 2013 through the INFORM 
program. Of the 3,902 isolates tested, 580 were MDR-P. aeruginosa and 338 were XDR-
P. aeruginosa. The MIC50 and MIC90 of ceftazidime-avibactam were 4/4 µg/ml and 16/4 
µg/ml, respectively, in the MDR-P. aeruginosa isolates. Comparatively, the MIC50 and 
MIC90 of ceftazidime alone were 32 µg/ml and >32 µg/ml, respectively, in the MDR-P. 
aeruginosa isolates. Eighty-one percent of MDR-P. aeruginosa isolates were susceptible 
to ceftazidime-avibactam. The MIC50 and MIC90 of ceftazidime-avibactam were 8/4 
µg/ml and 32/4 µg/ml, respectively, in the XDR-P. aeruginosa isolates. The MIC50 and 
MIC90 of ceftazidime alone were 32 µg/ml and > 32 µg/ml, respectively, in the XDR-P. 
aeruginosa isolates. Of the XDR-P. aeruginosa isolates, 73.7% were susceptible to 
ceftazidime-avibactam(27). While this surveillance study shows ceftazidime-avibactam’s 
promising in vitro activity in resistant P. aeruginosa, it also confirms the concern of 
XDR-P. aeruginosa. Without any institution-specific XDR-P. aeruginosa population 
characterization there would be hesitation to recommend ceftazidime-avibactam as 
empiric therapy for a suspected highly resistant infection when surveillance data 
estimates less than 75% susceptibility rates.    
In vitro analysis is the foundation for developing the effectiveness of an 
antimicrobial agent. Clinical trials build on in vitro analysis and show how the 
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antimicrobial agent works with other factors such as the immune system to result in 
clinical cure and eradication of the infection. Two trials of note that aided in the FDA 
approval of ceftazidime-avibactam are the REPRISE and REPROVE phase III trials that 
investigated the clinical use of ceftazidime-avibactam in hospitalized patients. The 
REPRISE trial was a prospective, multicenter, phase III trial that assessed the efficacy, 
safety, and tolerability of ceftazidime-avibactam compared to standard therapy in 
ceftazidime resistant gram-negative pathogens causing complicated urinary tract 
infections or complicated intra-abdominal infections between January 2013 to August 
2014. Of those randomized, 21 patients had a P. aeruginosa infection. The clinical cure 
rate of urinary tract infections by ceftazidime-avibactam compared to standard therapy 
was 86% (n=14) and 100% (n=5), respectively. The per pathogen favorable 
microbiological response was 79% and 60% in the ceftazidime-avibactam and standard 
therapy groups, respectively. Overall, ceftazidime-avibactam produced similar results as 
standard therapy and results supported other phase III trials with or without inclusion of 
resistant pathogens(29). 
The REPROVE trial was a phase III, multicenter trial investigating the use of 
ceftazidime-avibactam in hospitalized patients with hospital-acquired or ventilator-
associated pneumonia caused by a gram-negative pathogen. Between April 2013 and 
January 2016 patients were randomized to receive ceftazidime-avibactam or meropenem 
treatment on average ten days for nosocomial pneumonia. Among patients in the 
microbiological intention to treat population, 28.3% were infected with at least one gram-
negative pathogen non-susceptible to ceftazidime. There were 28 patients with non-
susceptible P. aeruginosa infections; 12 patients treated with ceftazidime-avibactam and 
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16 treated with meropenem. The MIC90 of ceftazidime and ceftazidime-avibactam against 
all 111 P. aeruginosa isolates in the microbiological intention to treat population were 64 
µg/ml and 8/4 µg/ml, respectively.  Overall, they determined that ceftazidime-avibactam 
was a noninferior treatment to meropenem(30). These trials both show the effectiveness 
of ceftazidime-avibactam in P. aeruginosa with some developed resistance. However, the 
clinical activity of ceftazidime-avibactam against the complex and highly resistant XDR-
P. aeruginosa is still unknown.    
1.4  CEFTOLOZANE-TAZOBACTAM 
Ceftolozane-tazobactam is another new beta-lactam/beta-lactamase inhibitor 
combination on the market with a special niche against P. aeruginosa infections. It is also 
FDA-approved for use in complicated intra-abdominal infections and complicated 
urinary tract infections including pyelonephritis(31). Unlike ceftazidime-avibactam, the 
beta-lactam ceftolozane is novel and provides unique activity against P. aeruginosa 
rather than the beta-lactamase inhibitor tazobactam. Ceftolozane is an 
oxyiminoaminothiazolyl cephalosporin that has stability against AmpC beta-lactamases, 
deletion of the OprD porin channel, and efflux pump production(26). Unlike ceftazidime-
avibactam, it overcomes the carbapenem resistance due to non-carbapenemase activity 
discussed in the previous section. This is one of the first antimicrobial agents to show 
protection against multiple mechanisms of resistance. Various surveillance studies show 
ceftolozane-tazobactam’s potent activity against P. aeruginosa and carbapenem-resistant 
P. aeruginosa(32–34).  
An early multicenter European surveillance study investigated the activity of 
ceftolozane-tazobactam in 2,191 P. aeruginosa isolates from 2011 to 2012. 31.9% of 
20 
 
isolates were MDR-P. aeruginosa and 24.6% XDR-P. aeruginosa. The MIC50 and MIC90 
of ceftolozane-tazobactam against all isolates were 1/4 µg/ml and >32/4 µg/ml, 
respectively. The overall susceptibility to ceftolozane-tazobactam was 84.5% of isolates. 
Of MDR-P. aeruginosa and XDR-P. aeruginosa isolates, 53.2% and 42.8% were 
susceptible to ceftolozane-tazobactam, respectively. The MIC50 and MIC90 of 
ceftolozane-tazobactam against MDR-P. aeruginosa were 4/4 µg/ml and >32/4 µg/ml, 
respectively. The MIC50 and MIC90 of ceftolozane-tazobactam against XDR-P. 
aeruginosa were 32/4 µg/ml and >32/4 µg/ml, respectively. Even though the MIC values 
are elevated for ceftolozane-tazobactam, it had the greatest activity compared to other 
beta-lactam agents tested(34). 
A second global surveillance study assessed the in vitro activity of ceftolozane-
tazobactam against 6,836 P. aeruginosa isolates, including MDR-P. aeruginosa and 
XDR-P. aeruginosa isolates, from 104 hospitals on four different continents between 
2015 and 2017. Europe had the highest overall rate of MDR-P. aeruginosa at 26.2%, but 
the rate slightly decreased from 27.2% to 24.7% overtime. This differed from the United 
States where the rate increased from 14.1% to 21.2% overtime. Of all P. aeruginosa 
isolates, 93.5% were susceptible to ceftolozane-tazobactam. Only 69.2% and 59.1% of all 
MDR-P. aeruginosa (n=1,421) and XDR-P. aeruginosa (n=1,034) isolates, respectively, 
were susceptible to ceftolozane-tazobactam. The overall susceptibility of ceftolozane-
tazobactam in each region remained constant over the three-year period. In the United 
States, 98% of P. aeruginosa isolates were susceptible in 2015 and 97.7% of isolates in 
2017. Finally, the overall MIC50 and MIC90 of ceftolozane-tazobactam were 0.5/4 µg/ml 
and 2/4 µg/ml, respectively. The MIC50 and MIC90 of ceftolozane-tazobactam against 
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MDR-P. aeruginosa isolates were 2/4 µg/ml and >32/4 µg/ml, respectively. The MIC50 
and MIC90 of ceftolozane-tazobactam  against XDR-P. aeruginosa isolates were 4/4 
µg/ml  and >32/4 µg/ml, respectively(35). Overall, ceftolozane-tazobactam had potent 
activity against P. aeruginosa that was not sustained in highly resistant isolates. While 
there have been numerous in vitro studies investigating the use of ceftolozane-tazobactam 
therapy, there have been limited clinical trials similar to ceftazidime-avibactam 
limitations. 
One phase III randomized control trial was the ASPECT-cIAI (Assessment of the 
Safety Profile and Efficacy of Ceftolozane-Tazobactam in Complicated Intra-abdominal 
Infections) trial. It was a prospective, double-blind trial across 196 study centers 
worldwide. They assessed the noninferiority of the clinical cure rate of ceftolozane-
tazobactam plus metronidazole compared to meropenem for the treatment of complicated 
intra-abdominal infections in hospitalized patients caused by gram-negative pathogens. 
Of the pathogens isolated, 72 (8.9%) were P. aeruginosa and 6 of which were considered 
MDR-P. aeruginosa. The MIC90 of ceftolozane-tazobactam and meropenem against P. 
aeruginosa were 1 µg/ml and 2 µg/ml, respectively. The rates of susceptibility of 
ceftolozane-tazobactam and meropenem for P. aeruginosa were 98.6% and 89.9%, 
respectively. The overall clinical cure rates for the ceftolozane-tazobactam plus 
metronidazole vs the meropenem groups were 83% and 87.3%, respectively. 
Ceftolozane-tazobactam plus metronidazole was concluded to be a noninferior treatment 
option to meropenem for complicated intra-abdominal infections(36). However, similar 
to the ceftazidime-avibactam clinical trials, the use in known resistant subpopulations is 
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unknown. There is a gap in clinical data for use of ceftolozane-tazobactam in XDR-P. 
aeruginosa, so our understanding is limited to in vitro studies.  
To build upon the foundational in vitro studies assessing ceftolozane-tazobactam 
activity or ceftazidime-avibactam activity, there have also been numerous surveillance 
studies comparing ceftolozane-tazobactam and ceftazidime-avibactam activity in the 
same P. aeruginosa isolates. This head-to-head comparison starts to help build an 
understanding of utility of each agent and which mechanisms of resistance might be at 
play for their P. aeruginosa populations. One multicenter in vitro study in the United 
States compared the activity of ceftazidime-avibactam and ceftolozane-tazobactam in 290 
meropenem non-susceptible P. aeruginosa isolates from 2013 to 2014. Isolate origins 
included bloodstream, respiratory, and wound infections. The MIC50 and MIC90 of 
ceftazidime-avibactam were 4/4 µg/ml and 16/4 µg/ml, respectively. The MIC50 and 
MIC90 of ceftolozane-tazobactam were 1/4 µg/ml and 4/4 µg/ml, respectively. 
Ceftolozane-tazobactam was more potent than ceftazidime-avibactam regardless of 
infection source. Ninety-one percent of isolates were susceptible to ceftolozane-
tazobactam compared to 81% of isolates were susceptible to ceftazidime-avibactam(32).  
A second comparator study investigated the susceptibility of P. aeruginosa 
isolates in the INFORM surveillance program to ceftolozane-tazobactam and 
ceftazidime-avibactam. P. aeruginosa isolates (n=1,909) from 70 United States medical 
centers in 2017 were utilized. The MIC50 and MIC90 of piperacillin-tazobactam were 4/4 
µg/ml and 128/4 µg/ml, respectively. 77.5% of isolates were susceptible to piperacillin-
tazobactam. Comparatively, the MIC50 and MIC90 of ceftazidime-avibactam were 2/4 
µg/ml and 8/4 µg/ml, respectively, and the MIC50 and MIC90 of ceftolozane-tazobactam 
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were 0.5/4 µg/ml and 2/4 µg/ml, respectively. Of all isolates, 96.9% and 97.5% were 
susceptible to ceftazidime-avibactam and ceftolozane-tazobactam, respectively. Isolates 
non-susceptible to ceftazidime, cefepime, piperacillin-tazobactam, and meropenem 
(n=161), 78.7% and 70.2% were susceptible to ceftolozane-tazobactam and ceftazidime-
avibactam, respectively(33). Both ceftolozane-tazobactam and ceftazidime-avibactam 
greatly improved activity against these isolates, with ceftolozane-tazobactam having 
lower MICs and greater susceptibility compared to ceftazidime-avibactam.       
Overall there are some studies starting to show ceftolozane-tazobactam’s greater 
in vitro activity in P. aeruginosa  when compared head-to-head to ceftazidime-
avibactam(32,33). Ceftazidime-avibactam may still be considered the agent of choice 
when carbapenemases are the primary mechanism of resistance, and ceftolozane-
tazobactam the agent of choice when there is an interplay of OprD downregulation and 
efflux pump system upregulation(12). Due to P. aeruginosa high inter-institutional 
resistance mechanism variability we needed to confirm the mechanisms of resistance at 
play. Then we can determine if these comparison surveillance study results hold true 
against our highly resistant P. aeruginosa isolates; assessing their potential empiric 
monotherapy use in severe hospital-acquired infections. 
 
 
 
 
 
24 
 
1.5  AZTREONAM-AVIBACTAM 
The final new antimicrobial combination of interest was aztreonam-avibactam 
due to aztreonam’s protection from MBL carbapenemases and avibactam’s KPC and 
AmpC activity. Aztreonam-avibactam is not an FDA approved combination therapy 
against P. aeruginosa causing infections and is not clinically used. In vitro studies have 
assessed its activity against various gram-negative organisms including P. aeruginosa. 
One study conducted at 11 hospitals in China from 2011 to 2012 investigated the in vitro 
activity of aztreonam-avibactam against 372 gram-negative bacilli. Of the 372 isolates, 
25 were P. aeruginosa and 11 of which were carbapenem non-susceptible and six MDR-
P. aeruginosa isolates.  The carbapenem non-susceptible isolates were positive for genes 
such as OXA-50 and/or TEM-1 beta-lactamases. The overall MIC50 and MIC90 of 
aztreonam alone were 16 µg/ml and 128 µg/ml, respectively, compared to 16/4 µg/ml and 
64/4 µg/ml, respectively, of aztreonam-avibactam against P. aeruginosa isolates. 
Twenty-eight percent of all P. aeruginosa isolates were susceptible to aztreonam alone 
and 36% were susceptible to aztreonam-avibactam. The MIC50 and MIC90 of aztreonam 
alone were 32 µg/ml and > 128 µg/ml, respectively, against MDR-P. aeruginosa 
compared to 32/4 µg/ml and > 128/4 µg/ml, respectively, of aztreonam-avibactam against 
MDR-P. aeruginosa. There was no change in MIC in these six resistant isolates(37). 
Overall, susceptibility was not restored with the addition of avibactam to aztreonam. 
Following this small in vitro P. aeruginosa study, a larger surveillance study 
investigated the in vitro activity of aztreonam-avibactam in 11,842 P. aeruginosa isolates 
collected from 208 medical centers in 40 countries between 2012 to 2015. The MIC50 and 
MIC90 of both aztreonam alone and aztreonam-avibactam (4 µg/ml) were 8 µg/ml and 32 
µg/ml, respectively. Of the 11,842 P. aeruginosa isolates, 452 were MBL-positive. The 
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MIC50 of both aztreonam and aztreonam-avibactam (4 µg/ml) in these isolates was 16 
µg/ml. The MIC90 of aztreonam and aztreonam-avibactam (4 µg/ml) in these isolates 
were 64 µg/ml and 32 µg/ml, respectively(38). Overall, there was an unimpressive 
change in MIC in all P. aeruginosa isolates as well as MBL-positive P. aeruginosa 
isolates with the addition of avibactam to aztreonam. In vitro data have not shown the 
same promising results for aztreonam-avibactam in P. aeruginosa as ceftazidime-
avibactam and ceftolozane-tazobactam. 
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CHAPTER 2. METHODOLOGY 
2.1 BACTERIAL ISOLATE SELECTION AND PREPARATION 
 The University of Kentucky Albert B. Chandler Medical Center Clinical 
Microbiology Laboratory utilizes BD Phoenix™ Automated System (Figure 3) to identify 
microbial organisms and determine antimicrobial minimum inhibitory concentrations and 
susceptibility routinely on patients with confirmed infection. P. aeruginosa isolates 
largely determined to be MDR or XDR were transferred to the University of Kentucky 
College of Pharmacy – Pharmacy Practice and Science Core Microbiology Laboratory 
for further testing. All BD Phoenix™ generated MIC data were transferred with the 
isolates. No patient specific information was included under the current IRB approval. 
Upon receipt, isolates were stored at -80°C in 10% glycerol in water solutions. Two 
hundred and eighty-seven isolates were collected between 2014 to 2017 and reviewed for 
selection. Eighty-three of the 287 isolates were considered XDR-P. aeruginosa. 
Additional selection criteria for the 49 isolates tested included non-susceptibility to both 
cefepime and ceftazidime, both levofloxacin and ciprofloxacin, both gentamicin and 
tobramycin, aztreonam, piperacillin-tazobactam, and meropenem.  
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Figure 3: BD Phoenix™ Automated System Utilized by the University of Kentucky 
HealthCare Clinical Microbiology Laboratory For Organism Identification and 
Susceptibility Testing(39) 
 
 
 
 
Prior to all experiments, all reusable equipment, sterile water, and Mueller-Hinton 
agar and broth (BD Difco™) were sterilized in an autoclave high pressure and 
temperature system (Figure 4). Mueller-Hinton agar and broth were prepared in one-liter 
batches through weighing 38 g of agar powder or 21 g of broth powder and dissolving in 
one liter of sterile water. The autoclave setting used for sterilization of both the broth and 
agar was 121°C for 30 minutes. Mueller-Hinton broth utilized for broth microdilution, 
Etest®, and Kirby-Bauer disk diffusion studies required that it be cation-adjusted 
according to the 2018 Clinical and Laboratory Standards Institute (CLSI) 28th edition 
guidelines(40). After the broth cooled from the autoclave, cation-adjusted Mueller Hinton 
broth (CAMHB) was prepared through adding calcium chloride and magnesium sulfate 
to produce final concentrations in the broth of 25 mg/L and 12.5 mg/L, respectively. A 10 
mg/ml stock solution of calcium chloride was prepared for use through measuring 3.68 g 
of CaCl2*H2O and dissolving in 100 ml of sterile water. A 10 mg/ml stock solution of 
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magnesium sulfate was prepared for use through measuring 8.36 g of MgCl2*H2O and 
dissolving in 100 ml of sterile water. The stock solutions were not autoclaved but were 
sterilized through filtration through a 0.22-micron filter. Stock solutions and CAMHB 
were stored at 4°C in between uses. CAMHB was used within two weeks of preparation, 
autoclaved Mueller Hinton agar was plated immediately following the below instructions 
“Etest,” and cations were used for several months.   
 
 
 
 
Figure 4: Autoclave System Utilized by the University of Kentucky Pharmacy Practice 
and Science Core Lab 
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Twenty-four hours prior to each experiment frozen P. aeruginosa isolates were 
prepared for use through a repeated subculture. In a 15 ml polypropylene conical 
centrifuge tube, 3-5 ml of CAMHB was inoculated with each frozen isolate using a sterile 
loop applicator. The lids of the centrifuge tubes were loosely placed to allow for 
oxygenation during incubation. Samples were then allowed to incubate at 37°C shaking 
at 220 RPM for at least four hours (Figure 5). During the incubation period a second 
polypropylene conical centrifuge tube was prepared with 3-5 ml of CAMHB ready for re-
inoculation using a second sterile loop applicator and the incubating liquid culture. Once 
re-inoculated, centrifuge tubes were incubated again at 37°C and 220 RPM until visibly 
turbid and needed for the experiment (~24hrs). All isolate manipulation was performed in 
a Class II laminar hood (Figure 6).         
 
 
Figure 5: ThermoFischer Scientific MaxQ 6000 Shaking Incubator 
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Figure 6: Biosafety Class II Laminar Hood Utilized by the University of Kentucky 
Pharmacy Practice and Science Core Laboratory 
 
 
 
 
 
2.2 SUSCEPTIBILITY TESTING 
 In vitro susceptibility testing was performed in duplicate on at least two separate 
occasions. Broth microdilution is considered the gold standard and when antimicrobial 
dry powders were available, broth microdilution was performed according to the 2018 
CLSI guidelines(40). When dry powders were unavailable, Etest® strip testing was 
utilized. MIC values generated by BD Phoenix™ Automated Systems susceptibility 
panel were confirmed for amikacin, aztreonam, ceftazidime, cefepime, levofloxacin, 
tobramycin, gentamicin, meropenem, and piperacillin-tazobactam. MIC values were 
determined for imipenem, colistin, polymyxin B, ceftolozane-tazobactam, ceftazidime-
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avibactam, and aztreonam-avibactam. MIC susceptibility breakpoints from the 2018 
CLSI guidelines were utilized (Table 1)(40). P. aeruginosa ATCC 27853 
was the control organism utilized, and the MIC quality control (QC) range recommended 
in the 2018 CLSI guidelines(40).  
 
 
Table 1: Antimicrobial Agent MIC Breakpoints (µg/ml) and Interpretive Categories for 
P. aeruginosa(40)   
Antimicrobial Susceptible Intermediate Resistant P. aeruginosa 
ATCC 27853 MIC 
QC Range 
Amikacin ≤ 16 32 ≥ 64 1-4 
Aztreonam ≤ 8 16 ≥ 32 2-8 
Aztreonam-
Avibactam* 
≤ 8/4 16/4 ≥ 32/4 2/4-8/4 
Cefepime ≤ 8 16 ≥ 32 0.5-4 
Ceftazidime ≤ 8 16 ≥ 32 1-4 
Ceftazidime-
Avibactam 
≤ 8/4 --- ≥ 16/4 0.5/4-4/4 
Ceftolozane-
Tazobactam 
≤ 4/4 8/4 ≥ 16/4 0.25/4-1/4 
Colistin ≤ 2 --- ≥ 4 0.5-4 
Gentamicin ≤ 4 8 ≥ 16 0.5-2 
Imipenem ≤ 2 4 ≥ 8 1-4 
Levofloxacin ≤ 2 4 ≥ 8 0.5-4 
Meropenem ≤ 2 4 ≥ 8 0.12-1 
Piperacillin-
Tazobactam 
≤ 16/4 32/4 – 64/4 ≥ 128/4 1/4-8/4 
Polymyxin B ≤ 2 4 ≥ 8 0.5-2 
Tobramycin ≤ 4 8 ≥ 16 0.25-1 
*CLSI does not have recommendations for aztreonam-avibactam breakpoints, so the 
same breakpoints recommended for aztreonam alone were utilized and the concentration 
of avibactam was 4 µg/ml. 
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2.2.1 BROTH MICRODULITION 
 Broth microdilution is a three-day experiment that requires isolate preparation, 
antimicrobial stock solution preparation, and equipment sterilization on Day 1; plating of 
the bacterial isolates and antimicrobial agent serial dilution into 96-well plates on Day 2; 
and then 16-20 hours of incubation at 37°C prior to MIC determination on Day 3. On 
Day 1 bacterial isolates were subcultured as described in “bacterial isolate selection and 
preparation.” Antimicrobial concentrated stock solutions were also prepared using 2018 
CLSI solvent and diluent recommendations (Table 2)(40) and the antimicrobial powder 
potency value stated in the certificate of analysis from the manufacturer of the product. 
Concentrated stock solutions were stored in between experiments at -20°C and used 
within a couple of weeks, except imipenem was made fresh for each experiment because 
it was not stable in solution.   
 
Table 2: Antimicrobial Agent and Inhibitor Stock Solution Preparation 
Agent Manufacturer Solvent  
(minimal volume) 
Diluent  
(qs 10 ml) 
Amikacin Sigma-Aldrich Sterile water Sterile water 
Avibactam Advanced 
Chemblocks Inc 
Sterile water Sterile water 
Aztreonam Sigma-Aldrich Saturated solution 
sodium bicarbonate* 
Sterile water  
Cefepime Sigma-Aldrich Phosphate buffer, pH 6, 
0.1 mol/L** 
Phosphate buffer, 
pH 6, 0.1 mol/L** 
Ceftazidime Sigma-Aldrich Sodium carbonate*** Sterile water 
Cloxacillin Sigma-Aldrich Sterile water Sterile water 
Colistin 
Sulfate 
Sigma-Aldrich Sterile water Sterile water 
Gentamicin Sigma-Aldrich Sterile water Sterile water 
Imipenem Sigma-Aldrich Phosphate buffer, pH 
7.2, 0.01 mol/L** 
Phosphate buffer, 
pH 7.2, 0.01 
mol/L** 
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Table 2 (continued) 
Levofloxacin Sigma-Aldrich ½ volume of sterile 
water, then 0.1 mol/L 
NaOH dropwise to 
dissolve**** 
Sterile water 
L-arginine Sigma-Aldrich Sterile water Sterile water 
Meropenem Ark Pharm Sterile water Sterile water 
Phenylalanine-
Arginine-β-
Naphthylamide 
(PAβN) 
Sigma-Aldrich Sterile water Sterile water 
Piperacillin Sigma-Aldrich Sterile water Sterile water 
Polymyxin B Sigma-Aldrich Sterile water Sterile water 
Tazobactam Sigma-Aldrich Sterile water Sterile water 
Tobramycin Sigma-Aldrich Sterile water Sterile water 
* The solubility of sodium bicarbonate at 25°C is 10.3 g/100 g of sterile water(41). 
Prepared a 10 ml solution of saturated sodium bicarbonate by dissolving 800 mg of 
sodium bicarbonate in 10 ml of sterile water. This solution was added dropwise to the 
aztreonam powder until dissolved and then qs to 10 ml with sterile water using a 
volumetric flask. 
**Prepared 10 ml of the desired phosphate buffer according to Figure 7 using monobasic 
and dibasic sodium phosphate. The figure created a 0.1 M solution and further dilution 
with sterile water was required to result in 0.01 M solution for imipenem. 
***Dissolved anhydrous sodium carbonate equivalent to 10% of the ceftazidime weight 
in 7-8 ml of the sterile water used to dilute the ceftazidime powder. Dissolved the 
ceftazidime powder in this solution and then qs to 10 ml with sterile water in a volumetric 
flask. 
****Partially dissolved the levofloxacin powder in half the volume of sterile water 
(~5ml). Then, added 0.1 mol/L of NaOH dropwise until completely dissolved and qs to 
10 ml with sterile water in a volumetric flask. 
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Figure 7: Sodium Phosphate Buffer Preparation 
 
 
On Day 2 a BioStack™ attached to a Precision™ Pipetting System (Figure 8) 
were utilized to measure and dispense all components of the broth microdilution into the 
individual wells of the 96-well plates. First, Program 1 file “BTK MIC Testing (Initial 50 
mcl broth only)” of the Precision Series application on the computer desktop pipetted 50 
µL of CAMHB from the 4x1 reservoir (Figure 9a) and dispensed in each well of the 96-
well plate. While Program 1 was running an aliquot of the concentrated antimicrobial 
agent stock solution was diluted in CAMHB to a concentration that when dispensed in 
the 96-well plates, produced the desired starting concentration of the antimicrobial agent 
in Column 1 (Figure 10). Both the MIC breakpoints of each antimicrobial agent and 
control organism MIC QC range for the agent needed to fit on one plate (within 11 
dilutions). For example, the stock solution of amikacin made was 20.48 mg/ml. This was 
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then diluted 1:10 with CAMHB (total volume 12-15 ml) to produce a concentration of 
512 µg/ml in Column 1 and 0.5 µg/ml in Column 11. The MIC breakpoint for amikacin is 
≥ 64 µg/ml and the MIC QC range is 1-4 µg/ml (Table 1). The exception to these 
calculations was when a beta-lactamase inhibitor was included because the total volume 
in each well was then 125 µl instead of 100 µl. This was accounted for through an initial 
dilution of 1.25 parts of drug to 8.75 parts of CAMHB. The concentration range for each 
antimicrobial agent on the 96-well plate was as follows: gentamicin (256 µg/ml – 0.25 
µg/ml), tobramycin (128 µg/ml – 0.125 µg/ml), amikacin (512 µg/ml – 0.5 µg/ml), 
levofloxacin (256 µg/ml – 0.25 µg/ml), cefepime (256 µg/ml – 0.25 µg/ml), ceftazidime 
(256 µg/ml – 0.25 µg/ml), ceftazidime-avibactam (256/4 µg/ml – 0.25/4 µg/ml), 
meropenem (128 µg/ml – 0.125 µg/ml), imipenem (128 µg/ml – 0.125 µg/ml),  
piperacillin-tazobactam (512/4 µg/ml – 0.5/4 µg/ml), aztreonam (256 µg/ml – 0.25 
µg/ml), aztreonam-avibactam (256/4 µg/ml – 0.25/4 µg/ml), colistin (128 µg/ml – 0.125 
µg/ml), and polymyxin B (64 µg/ml – 0.0625 µg/ml). Then, Program 2 file “BTK 
multiDrug MIC Testing (11 dilutions)” pipetted 50 µL of each antimicrobial agent from 
the appropriate well of the 4x1 reservoir in the eight wells that make up Column 1 of the 
96-well plate. It then moved across the plate providing a serial dilution until it reached 
Column 12 of the plate. At which point it did not dispense any drug, allowing the column 
to serve as the growth control wells for each drug. If utilizing an antimicrobial agent with 
a beta-lactamase inhibitor like piperacillin-tazobactam, Program 2.5 file “BTK Drug PIP 
TAZO MIC Testing” allowed for the beta-lactamase inhibitor diluted in CAMHB 
following the above methodology (total volume ~ 35 ml) to be measured and dispensed at 
an equal concentration of 4 µg/ml in each well through pipetting 25 µL from the 4x1 
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reservoir and dispensing in each well. If an antimicrobial agent that did not have an 
inhibitor was run on the same plate as an agent with an inhibitor, then an additional 25 
µL of CAMHB was added.   
 
 
 
 
Figure 8: BioStack™ and Precision™ Pipetting System 
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A            B 
 
Figure 9: (A)4x1 Reservoir Utilized for CAMHB and Antimicrobial Agent Application 
(B)1x6 Reservoir Utilized for XDR-P. aeruginosa Application 
 
 
 
 
Figure 10: Broth Microdilution 96-Well Plate Set-Up(42) 
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 Finally, Program 3 file “BTK multiBug MIC Testing (Lay bug 50 mcl)” added 
the P. aeruginosa isolate to each plate. The program pipetted 50 µL of isolate from the 
appropriate well of a 1x6 reservoir (Figure 9b) and dispensed in each well of the 96-well 
plate. Each of the six wells of the reservoir had a different bacterial isolate and the 
program sequentially used each reservoir well for one entire 96-well plate. Bacterial 
isolate subcultures required further dilution and manipulation prior to plating during 
Program 3. In a glass test tube filled with 2-4 ml of sterile water, using a P1000 
micropipette, the bacterial isolate subculture was added dropwise until the desired isolate 
concentration achieved. Using 0.5 and 1.0 McFarland Standards and a Wickerham Card 
the turbidity of the glass test tube was matched to a turbidity between the two standard 
turbidities with the goal of creating a turbidity closer to the 0.5 Standard (Figure 11). 
When the appropriate turbidity was reached, then the desired bacterial concentration of 
~1-1.5 x 108 CFU/ml was reached. To reach a final concentration of bacteria in each well 
of 5-7.5 x 105 CFU/ml, a 1:200 dilution was performed through taking 100 µl of the 
resultant solution in the glass test tube and adding it to 9.9 ml of CAMHB in a 15 ml 
polypropylene conical centrifuge tube. The contents of this tube were then poured in a 
single well of the 6x1 reservoir and were ready to be plated.     
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Figure 11: 0.5 (right) and 1 (left) McFarland Standard and Wickerham Card Set-Up 
 
 
Once all the components were added to the plates by the BioStack™ and 
Precision™ Pipetting System, the lids were placed on top of each individual plate and the 
plates were incubated for 16-20 hrs at 37°C (Figure 12). The MIC determined was the 
concentration of the antimicrobial agent in the first well where there was no visible 
turbidity or bacterial growth (Figure 10). This included wells with incomplete or partial 
growth. Each isolate was recorded on an individual sheet reflective of each 96-well plate, 
and then all MIC values input into the isolate database on the lab drive (Figure 13). Pages 
were also scanned into the computer and saved to the lab drive. Each antimicrobial agent 
susceptibility was considered to be completed in duplicate because two identical rows of 
the 96-well plate contained the same agent (Figure 10). All methodology was repeated so 
that each antimicrobial agent was completed for each isolate at least in duplicate on two 
separate occasions. If all four MIC values were not in agreement, within a 2-fold MIC 
range (ie. 8 µl/ml, 16 µl/ml, and 32 µl/ml agree that the MIC is 16 µl/ml), then it was 
repeated on a third occasion. 
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Figure 12: Heratherm™ Incubator Utilized During Final Incubation Periods 
 
 
 
Figure 13: Document Utilized to Record Results From 96-well Plate  
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2.2.2 ETEST® 
Ceftolozane-tazobactam powder was unavailable for use, but Etest® (bioMérieux) 
of ceftolozane-tazobactam was available and the MIC for each isolate was determined. 
First, sterilized liquid Mueller-Hinton agar was poured into 100x15 mm petri dishes 
using an MP-1000 PourMatic® 100 mm (Figure 14). The plates were allowed time to 
solidify, and then were stored at -4°C. Plates were used within three months of 
preparation.  Following the methodology in “bacterial isolate selection and preparation” 
and “broth microdilution” bacterial isolates were subcultured and diluted using 
McFarland Standards. However, instead of further diluting and creating a 1:200 dilution 
with the glass test tube solution, a sterile swab was directly submerged in the solution, 
and then used to coat the agar with bacterial isolate. The entire surface of agar was 
swabbed in a back and forth motion, and the plate allowed to dry. Using sterilized forceps 
Etest® strips were then placed on the agar surface, all air bubbles removed, the lid of the 
dish replaced, and the strip allowed to dry. This prevented movement of the strip and 
inappropriate drug diffusion into the agar when the plate was inverted for incubation. 
Plates were incubated at 37°C for 16-20 hours. The MIC was determined by where the 
ellipse of colony clearing met the strip (Figure 15). The Etest® strip ceftolozane-
tazobactam concentration gradient ranged from 0.016 µg/ml – 256 µg/ml.  
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Figure 14: MP-1000 PourMatic® 100 mm System 
 
 
 
  
Figure 15: Etest® MIC Determination Utilized for Ceftolozane-Tazobactam Activity 
Against XDR-P. aeruginosa(43)  
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2.3 MECHANISM OF RESISTANCE PHENOTYPIC TESTING 
 
2.3.1 K. PNEUMONIAE CARBAPENEMASE AND METALLO-BETA-
LACTAMASE PHENOTYPIC EXPRESSION 
 Kirby Bauer disk diffusion was used to phenotypically detect KPC and MBL 
carbapenemases. Mueller-Hinton agar plates were made using the above methodology 
“bacterial isolate selection and preparation” and “Etest®.” Bacterial isolates were 
subcultured, diluted, and swabbed according to the above methodology “bacterial isolate 
selection and preparation,” “broth microdilution,” and “Etest®.” Using sterilized forceps, 
three Kirby Bauer disks were placed on the agar equidistant from each other (Figure 16a). 
Imipenem stock solution was prepared following the above methodology “broth 
microdilution.” Using the stock solution each disk was inoculated with 10 µg of 
imipenem. The stock solution was not further diluted because the volume added to the 
disc needed to be minimal (ie. 1.95 µl of imipenem 5.12 mg/ml stock solution were 
added to each disc). EDTA is a known inhibitor of MBL enzymes and phenylboronic 
acid (PBA) is a known inhibitor of both KPC enzymes and AmpC-beta-lactamase 
enzymes(22,23). A 75 mg/ml stock solution of EDTA was prepared by dissolving 750 
mg of EDTA in sterile water using a 10 ml volumetric flask. An 80 mg/ml stock solution 
of PBA was prepared by dissolving 808.08 mg (purity=99%) of PBA in DMSO using a 
10 ml volumetric flask.  
After disks were inoculated with either 518 µg (6.9 µl) of EDTA or 400 µg (5 µl) 
of PBA, the lid was replaced, the plate allowed to dry, the plate inverted, and then 
incubated at 37°C for 16-18 hours. The diameter of the zone of inhibition was measured 
with a ruler and recorded in the lab notebook and electronically inputted in the isolate 
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database on the lab drive (Figure 16a). The zone of inhibition diameter included the 
diameter of the disc itself. When the zone of inhibition had both a clear diameter and 
surrounding halo of partial inhibition, both diameters were recorded but only clear 
inhibition was used to measure the difference in the zones of inhibition (Figure 16b). 
MBL production was present if the difference in the zones of inhibition between the disc 
inoculated with 10 µg of imipenem alone and the disc inoculated with 10 µg of imipenem 
and 518 µg of EDTA was greater than or equal to 8 mm(23). For example, an isolate 
would be considered positive for MBL production if the diameter of the zone of 
inhibition of the imipenem disc was 8 mm and the zone of inhibition of the imipenem 
plus EDTA disc was 17 mm because the difference in diameter is 9 mm. For detection of 
KPC or AmpC enzymes, disks inoculated with 10 µg of imipenem alone or 10 µg of 
imipenem and 400 µg of PBA were compared. If the difference in the zones of inhibition 
was greater than or equal to 5 mm, the isolate was considered positive for KPC or AmpC 
expression (Figure 16a)(22). For example, an isolate would be considered positive for 
KPC or AmpC production if the diameter of the zone of inhibition of the imipenem disc 
was 14 mm and the zone of inhibition of the imipenem plus PBA disc was 25 mm 
because the difference in diameter is 11 mm. Isolates were then considered positive to 
KPC and not AmpC once AmpC production was ruled out through the below protocol 
“AmpC-β-lactamase Expression…” The positive control isolates for MBL and KPC 
expression alone were K. pneumoniae ATCC 2146 and ATCC 1705, respectively. The 
wildtype control isolate utilized was K. pneumoniae ATCC 700603. The negative control 
organism utilized was K. pneumoniae ATCC 1706. 
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A 
  
B 
 
Figure 16: Kirby-Bauer Disk Diffusion for Detection of MBL and KPC or AmpC 
Enzymes.  
(A)Clear and measurable zone of inhibition (I=imipenem alone; IP=imipenem and PBA; 
IE=imipenem and EDTA; red brackets=diameter of the zone of inhibition) (B)Haloed 
zone of inhibition (red brackets=diameter of the clear zone of inhibition; purple 
brackets=additional partial inhibition) 
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2.3.2 AMPC-BETA-LACTAMASE EXPRESSION, OPRD PORIN CHANNEL 
DOWNREGULATION, AND RND EFFLUX PUMP SYSTEM EXPRESSION 
Broth microdilution following the above protocol “broth microdilution” was 
performed to phenotypically detect the presence of AmpC-beta-lactamase, OprD porin 
channel inactivation, and RND efflux pump system expression. The antimicrobial agents 
utilized included imipenem, meropenem, and cefepime. Their stock solutions and 
aliquots were prepared following the “broth microdilution” methodology and Table 2, 
and they were plated using Program 2 of the BioStack™ and Precision™ Pipetting 
System. The inhibitors used include cloxacillin a known inhibitor of AmpC production, 
L-arginine a substrate of OprD porin channels, and PA𝝱N a non-specific inhibitor of 
RND efflux pump systems(10,14,15,44,45). Stock solutions for each inhibitor were 
prepared using the listed diluent and solvent in Table 2. A 10 mg/ml cloxacillin stock 
solution was prepared and 250 µg/ml resulted in each well. A 0.4 M stock solution of L-
arginine (FW=174.2 g/mol) was prepared by dissolving 697 mg of L-arginine in sterile 
water in a 10 ml volumetric flask, and 10 mM resulted in each well. A 0.8 mg/ml stock 
solution of PAβN was prepared and 20 µg/ml resulted in each well. Each inhibitor was 
plated using Program 2.5 of the BioStack™ and Precision™ Pipetting System.  
To detect AmpC production and OprD production the MICs of imipenem and 
meropenem alone were compared to imipenem and meropenem combined with the 
respective inhibitor. To detect the production of efflux pump systems the MICs of 
meropenem and cefepime alone were compared to meropenem and cefepime combined 
with PA𝝱N. The isolate was considered positive for AmpC production if the MIC of 
either meropenem or imipenem alone decreased by at least two-fold in the presence of 
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250 μg/mL of cloxacillin(14,44,45). For example, an isolate was considered AmpC 
production positive if the MIC of imipenem was 32 µg/ml and the MIC of imipenem plus 
cloxacillin was 16 µg/ml; a 2-fold decrease in MIC. Isolates determined to be positive for 
AmpC production were then compared to the isolates considered positive to either KPC 
or AmpC production through the Kirby Bauer disk diffusion test. This served as a second 
verification of AmpC production results and determined which isolates were positive for 
KPC production and not AmpC production. Isolates were not considered positive for 
production of both enzymes. Next, the isolate was considered positive for OprD porin 
channel downregulation if the MIC of either imipenem or meropenem remained 
unchanged in the presence of 10 mM of L-arginine(15). For example, an isolate was 
considered OprD inactivation positive if the MIC of imipenem was 16 µg/ml and the 
MIC of imipenem plus arginine was 16 µg/ml. The MIC did not change because there 
was not a significant number of OprD channels present and utilized for imipenem entry 
that were then subsequently blocked by L-arginine. The isolate was considered positive 
for efflux pump system utilization if the MIC of either meropenem or cefepime alone 
decreased by at least two-fold in the presence of 20 μg/mL of PA𝝱N(10,14,15). For 
example, an isolate was considered positive for efflux pump system utilization if the MIC 
of meropenem was 32 µg/ml and the MIC of meropenem plus PA𝝱N was 8 µg/ml; a 4-
fold decrease in MIC. Finally, P. aeruginosa ATCC 27853 was the control organism 
utilized. 
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2.4 STATISTICAL ANALYSIS 
 The MIC50, MIC90, and percent susceptible were determined for each 
antimicrobial agent. A McNemar test with an α of 0.05 was utilized to determine if agents 
had a significant difference in susceptibility against our XDR-P. aeruginosa isolates. 
Agents with greater than 80% susceptibility were compared to each other. These agents 
included colistin, polymyxin B, amikacin, ceftazidime-avibactam, and ceftolozane-
tazobactam. The beta-lactam/beta-lactamase inhibitor pairs were also compared to each 
other. For example, aztreonam was compared to aztreonam-avibactam, ceftazidime 
compared to ceftazidime-avibactam, and piperacillin-tazobactam compared to 
ceftolozane-tazobactam. Finally, to compare the United States surveillance data, 
University of Kentucky HealthCare Clinical Microbiology Laboratory BD Phoenix™ 
data, and University of Kentucky Pharmacy Practice and Science Core Microbiology 
Laboratory susceptibility data for each agent, Chi-square was utilized to compare broth 
microdilution data to surveillance date and McNemar was utilized to compare broth 
microdilution data to BD Phoenix™ data. A Bonferroni correction for the 14 total 
comparisons set significance at p<0.0036. 
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CHAPTER 3. RESULTS 
 
 
The Clinical Microbiology Laboratory at the University of Kentucky HealthCare 
isolated 287 P. aeruginosa isolates between 2014-2017, assessed their in vitro 
susceptibility to a panel of antimicrobial agents utilizing BD Phoenix™ Automated 
Systems, and then transferred them to the University of Kentucky Pharmacy Practice and 
Science Core Microbiology Laboratory for further assessment. Antipseudomonal agents 
included in the susceptibility panel were gentamicin, tobramycin, amikacin, 
ciprofloxacin, levofloxacin, meropenem, cefepime, ceftazidime, piperacillin-tazobactam, 
and aztreonam. Of the 287 P. aeruginosa isolates received, 138 (48%) were MDR-P. 
aeruginosa (non-susceptible to at least one agent from at least three antipseudomonal 
agent categories) and 83 (29%) were considered XDR-P. aeruginosa (non-susceptible to 
at least one agent in all but two or less of the antipseudomonal agent categories) 
(Appendix Table 1). These isolates have overall lower susceptibilities than the total 5000 
P. aeruginosa isolates that have been seen over the past ten years. The greatest 
susceptibility was amongst the aminoglycosides with amikacin at 94%, tobramycin at 
62%, and gentamicin at 54%.  Beta-lactams, including carbapenems, cephalosporins, and 
beta-lactam/beta-lactamase inhibitors had poor activity with <45% susceptibility 
(Appendix Table 2). The 2018 University of Kentucky HealthCare antibiogram for beta-
lactam susceptibility in comparison was cefepime (77%), ceftazidime (83%), meropenem 
(75%), and piperacillin-tazobactam (81%).    
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From the 287 P. aeruginosa isolates, the most resistant isolates were chosen for 
further analysis. Using the BD Phoenix™ susceptibility data and CLSI recommended 
breakpoints(40), 49 isolates from the 83 XDR-P. aeruginosa isolates were selected 
because they were considered non-susceptible to gentamicin, tobramycin, meropenem, 
aztreonam, piperacillin-tazobactam, cefepime, ceftazidime, levofloxacin, and 
ciprofloxacin (Appendix Table 3). Essentially, these isolates were non-susceptible to as 
many of the agents tested by the BD Phoenix™ Automated System as possible. Many of 
these isolates were only susceptible to amikacin. Broth microdilution is considered the 
gold standard in determining the MIC and in vitro susceptibility of an agent. Broth 
microdilution of agents from all antipseudomonal categories was performed to confirm 
these susceptibilities generated by BD Phoenix™ Automated Systems as well as 
determine the activity of agents not included in the panel. These agents included 
imipenem, colistin, polymyxin B, ceftolozane-tazobactam, ceftazidime-avibactam, and 
aztreonam-avibactam. All 49 XDR-P. aeruginosa isolates were tested, but one isolated 
(isolate #338 Appendix Table 2) was excluded from analysis due to possible 
contamination of storage vials and inability to verify results on multiple occasions.  
BD Phoenix™ Automated Systems overall resulted in comparable categorical 
susceptibilities to broth microdilution for these XDR-P. aeruginosa isolates. The two 
methodologies were considered to be in essential agreement if the resulting MICs were 
within one dilution of each other. This was difficult to assess in the majority of isolates 
due to the limited MIC range of BD Phoenix™ Automated Systems. The two 
methodologies were considered to be in categorical agreement if they resulted in the 
same susceptibility category for each isolate (susceptible, intermediate, or resistant). For 
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isolates not in categorical agreement, it was determined to be a minor error, major error, 
or very major error. If one test method resulted in susceptible or resistant and the other 
method intermediate, then it was considered a minor error. It was a major error if BD 
Phoenix™ categorized an isolate resistant and broth microdilution susceptible. It was a 
very major error if BD Phoenix™ categorized an isolate susceptible and broth 
microdilution resistant(46). For all antimicrobial agents tested by both BD Phoenix™ and 
broth microdilution they were considered in categorical agreement 85.3% of the time. Of 
the instances when there was categorical disagreement, 95.3% were due to minor error, 
3.1% due to major error, and 1.6% due to very major error (Appendix Table 5). 
Colistin and polymyxin B had the greatest activity at 100% of XDR-P. 
aeruginosa isolates (n=48) were susceptible. Apart from colistin and polymyxin B, 
ceftolozane-tazobactam had the greatest susceptibility at 94% of isolates with an MIC50 
of 1/4 µg/ml and MIC90 of 4/4 µg/ml (Figure 17, Table 3, Appendix Table 4). 
Ceftazidime-avibactam and amikacin followed closely with 90% and 83% of isolates 
susceptible, respectively. The MIC50 and MIC90 of ceftazidime-avibactam were 4/4 µg/ml 
and 16/4 µg/ml, respectively. The activity of ceftolozane-tazobactam was not 
significantly higher than ceftazidime-avibactam (p=0.6831) nor amikacin (p=0.1306). 
The activity of ceftazidime-avibactam was not significantly different from amikacin 
(p=0.505). The activity of colistin and polymyxin B were not significantly greater than 
ceftolozane-tazobactam (p=0.2482) or ceftazidime avibactam (p=0.0736). However, the 
activity of colistin and polymyxin B were significantly greater than amikacin (p=0.0133). 
Aztreonam-avibactam, on the other hand, had much lower activity at 40% of isolates 
were susceptible. The MIC50 and MIC90 of aztreonam-avibactam were 16/4 µg/ml and 
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64/4 µg/ml, respectively. All other antimicrobial agents tested (aztreonam, ceftazidime, 
gentamicin, imipenem, meropenem, piperacillin-tazobactam, and tobramycin) had <8% 
susceptibility, generally confirming the susceptibility data generated by BD PhoenixTM in 
the Clinical Microbiology Laboratory at the University of Kentucky HealthCare.  
 
Table 3: Antimicrobial Susceptibility Profile of XDR-P. aeruginosa (n=48) 
Antimicrobial % Susceptible MIC50 (µg/ml) MIC90 (µg/ml) 
Gentamicin 0 >256 >256 
Tobramycin 0 >128 >128 
Amikacin 83 16 32 
Piperacillin-
Tazobactam 
0 256/4 >512/4 
Levofloxacin 0 64 128 
Imipenem 0 16 32 
Meropenem 0 32 64 
Cefepime 0 32 128 
Aztreonam 8 64 128 
Aztreonam-
Avibactam 
40 16/4 64/4 
Ceftazidime 6 32 128 
Ceftazidime-
Avibactam 
90 4/4 16/4 
Ceftolozane-
Tazobactam 
94 1/4 4/4 
Polymyxin B 100 0.5 1 
Colistin 100 1 1 
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Figure 17: Antimicrobial Susceptibility Profile of XDR-P. aeruginosa (n=48) 
 
 
The susceptibility data of many antipseudomonal agents, including ceftolozane-
tazobactam and ceftazidime-avibactam, against the 48 selected XDR-P. aeruginosa 
isolates generated by broth microdilution in the University of Kentucky Pharmacy 
Practice and Science Core Microbiology Laboratory was compared to data generated by 
BD Phoenix™ in the Clinical Microbiology Laboratory at University of Kentucky 
HealthCare as well as United States surveillance programs. The INFORM group has 
assessed in vitro susceptibilities including ceftazidime-avibactam in 393 XDR-P. 
aeruginosa from various institutions and the PACTS (Program to Assess Ceftolozane-
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Tazobactam Susceptibility) group has assessed ceftolozane-tazobactam in 292 XDR-P. 
aeruginosa from institutions across the country. There were no statistically significant 
differences between BD Phoenix™ Automated Systems and broth microdilution. There 
were some differences between broth microdilution and United States surveillance 
studies. Differences between the groups in gentamicin, tobramycin, piperacillin-
tazobactam, meropenem, cefepime, and ceftazidime were not clinically relevant even 
though many were statistically significant (Table 4). They were not clinically relevant 
because all had poor susceptibility at much less than 80% of isolates susceptible to the 
agent. While not statistically different, the differences between the three groups in 
amikacin susceptibility data is clinically relevant. BD Phoenix™ data of 94% susceptible 
indicates amikacin is a valid agent of choice while broth microdilution determined only 
83% susceptible and surveillance data 78.6% susceptible. The latter values lead to 
hesitation in clinical recommendations unlike the BD Phoenix™ generated value. Our 
population of XDR-P. aeruginosa favor the use of both ceftolozane-tazobactam and 
ceftazidime-avibactam more than surveillance studies. Ceftolozane-tazobactam had 94% 
susceptibility from broth microdilution compared to 85.3% susceptibility from the 
surveillance study (p=0.112). Ceftazidime-avibactam had 90% susceptibility from broth 
microdilution compared to 80.4% susceptibility from the surveillance study (p=0.123). 
Characterizing the mechanisms of resistance utilized by XDR-P. aeruginosa at our 
institution provided insight into why they are non-statistically significantly more 
susceptible to these new agents compared to the general United States, but first a more 
detailed analysis comparing the activity of these new agents.          
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Table 4: Comparison of BD Phoenix™, US Surveillance Programs, and Broth 
Microdilution Susceptibility Data of XDR-P. aeruginosa  
(BMD=broth microdilution; Phon=BD Phoenix™; US=US Surveillance Programs) 
Antimicrobial US 
Surveillance 
Programs(35,4
7) 
(n=393) 
BD Phoenix™ 
(n=48) 
Broth 
Microdilution 
(n=48) 
p-value 
(BMD v Phon) 
(BMD v US) 
Gentamicin 
MIC50  
MIC90 
Susceptibility 
 
8 µg/ml 
>8 µg/ml 
37.4% 
 
--- 
--- 
0% 
 
>256 µg/ml 
>256 µg/ml 
0% 
 
 
--- 
2.11 x 10-7* 
Tobramycin 
MIC50  
MIC90 
Susceptibility 
 
2 µg/ml 
>8 µg/ml 
63.3% 
 
--- 
--- 
0% 
 
>128 µg/ml 
>128 µg/ml 
0% 
 
 
--- 
6.39 x 10-17* 
Amikacin 
MIC50  
MIC90 
Susceptibility 
 
8 µg/ml 
>32 µg/ml 
78.6% 
 
--- 
--- 
94% 
 
16 µg/ml 
32 µg/ml 
83% 
 
 
0.131 
0.449 
Piperacillin-
Tazobactam 
MIC50  
MIC90 
Susceptibility 
 
 
64/4 µg/ml 
>64/4 µg/ml 
7.1% 
 
  
--- 
--- 
0% 
 
 
256/4 µg/ml 
>512/4 µg/ml 
0% 
 
 
 
--- 
0.056 
Levofloxacin 
MIC50  
MIC90 
Susceptibility 
 
>4 µg/ml 
>4 µg/ml 
6.9% 
 
--- 
--- 
0% 
 
64 µg/ml 
128 µg/ml 
0% 
 
 
--- 
0.061 
Meropenem 
MIC50  
MIC90 
Susceptibility 
 
16 µg/ml 
32 µg/ml 
5.3% 
 
--- 
--- 
0% 
 
32 µg/ml 
64 µg/ml 
0% 
 
 
--- 
0.101 
Cefepime 
MIC50  
MIC90 
Susceptibility 
 
16 µg/ml 
>16 µg/ml 
20.9% 
 
--- 
--- 
0% 
 
32 µg/ml 
128 µg/ml 
0% 
 
 
 
0.00045* 
Aztreonam 
MIC50  
MIC90 
Susceptibility 
 
--- 
--- 
--- 
 
--- 
--- 
0% 
 
64 µg/ml 
128 µg/ml 
8% 
 
 
0.134 
--- 
Ceftazidime 
MIC50  
MIC90 
Susceptibility 
 
32 µg/ml 
>32 µg/ml 
23.7% 
 
--- 
--- 
0% 
 
32 µg/ml 
128 µg/ml 
6% 
 
 
0.248 
0.0058 
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Table 4 (continued) 
Ceftazidime-
Avibactam 
MIC50  
MIC90 
Susceptibility 
 
 
4/4 µg/ml 
16/4 µg/ml 
80.4% 
 
 
------------------ 
 
 
4/4 µg/ml 
16/4 µg/ml 
90% 
 
 
 
--- 
0.123 
Ceftolozane-
Tazobactam† 
MIC50  
MIC90 
Susceptibility 
 
 
2/4 µg/ml 
16/4 µg/ml 
85.3% 
 
 
------------------ 
 
 
1/4 µg/ml 
4/4 µg/ml 
94% 
 
 
 
--- 
0.112 
Colistin 
MIC50  
MIC90 
Susceptibility 
 
1 µg/ml 
1 µg/ml 
99% 
 
------------------- 
 
1 µg/ml 
1 µg/ml 
100% 
 
 
--- 
0.483 
*significant p-value (α=0.0036 with Bonferroni correction) 
†Surveillance data of ceftolozane-tazobactam in vitro activity against XDR-P. 
aeruginosa (n=292) was from the Program to Assess Ceftolozane-Tazobactam 
Susceptibility (PACTS) while all other agents were assessed by the INFORM group 
 
 
 When comparing the MICs of ceftolozane-tazobactam and ceftazidime-
avibactam, the MIC of ceftazidime-avibactam for each isolate was on the median four 
times greater than the MIC of ceftolozane-tazobactam; therefore, ceftolozane-tazobactam 
was more potent (Figure 18). Ceftolozane-tazobactam had the greatest decrease in MIC 
with a median 256-fold decrease in MIC when compared to the MIC of piperacillin-
tazobactam for each isolate. Ceftazidime-avibactam had a median 8-fold decrease in MIC 
when compared to the MIC of ceftazidime alone for each isolate. Aztreonam-avibactam 
had minimal change in MIC with a median 2-fold decrease in MIC when compared to the 
MIC of aztreonam alone for each isolate (Table 5, Table 6, Appendix Table 6). The 
change in susceptibility for each pair was significant; piperacillin-tazobactam to 
ceftolozane-tazobactam (p<0.0001), ceftazidime to ceftazidime-avibactam (p<0.0001), 
and aztreonam to aztreonam-avibactam (p=0.0003) (Table 5). Even though the change in 
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MIC was statistically significant for each pair, the two clinically relevant changes in MIC 
or susceptibility were those from piperacillin-tazobactam to ceftolozane-tazobactam and 
ceftazidime to ceftazidime-avibactam. Finally, when comparing overall susceptibility of 
the isolates to the new combination agents ceftolozane-tazobactam, ceftazidime-
avibactam, and aztreonam-avibactam; 38% of isolates were susceptible to all three agents 
and 48% were susceptible to both ceftolozane-tazobactam and ceftazidime-avibactam. 
Eight percent of isolates were susceptible only to ceftolozane-tazobactam, 4% of isolates 
were susceptible to only ceftazidime-avibactam, and 2% of isolates were susceptible to 
only aztreonam-avibactam (Table 7). No isolate was considered non-susceptible to all 
three agents. 
 
 
 
Figure 18: Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam MIC in 
XDR-P. aeruginosa (n=48) 
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Table 5: Change in Activity Between Beta-Lactam/Beta-Lactamase Inhibitors Against 
XDR-P. aeruginosa (n=48) 
Antimicrobial MIC50 
(µg/ml) 
MIC90 
(µg/ml) 
Susceptibility p-value 
Piperacillin-Tazobactam 256/4 >512/4 0% <0.0001 
Ceftolozane-Tazobactam 1/4 4/4 94%  
Ceftazidime 32 128 6% <0.0001 
Ceftazidime-Avibactam 4/4 16/4 90%  
Aztreonam 64 128 8% 0.0003 
Aztreonam-Avibactam 16/4 64/4 40%  
 
 
 
Table 6: Overall Fold Decrease in MIC Between Old and New Beta-Lactam/Beta-
Lactamase Inhibitors Against XDR-P. aeruginosa (n=48) 
 From Piperacillin-
Tazobactam To 
Ceftolozane-
Tazobactam 
From Ceftazidime 
To Ceftazidime-
Avibactam 
From Aztreonam 
To Aztreonam-
Avibactam 
Average 
Decrease in 
MIC 
288.6 – fold  9.5 – fold  3.3 – fold  
Median 
Decrease in 
MIC 
256 – fold  8 – fold  2 – fold  
 
 
 
Table 7: Comparison of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and 
Aztreonam-Avibactam Activity Against XDR-P. aeruginosa (n=48) 
Susceptibility % of Isolates 
Susceptible to ceftolozane-tazobactam, ceftazidime-avibactam, and 
aztreonam-avibactam 
38 
Susceptible to ceftolozane-tazobactam and ceftazidime-avibactam only 48 
Susceptible to ceftolozane-tazobactam and aztreonam-avibactam only 0 
Susceptible to ceftazidime-avibactam and aztreonam-avibactam only 0 
Susceptible to ceftolozane-tazobactam only 8 
Susceptible to ceftazidime-avibactam only 4 
Susceptible to aztreonam-avibactam only 2 
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Antimicrobial agents considered most active against this highly resistant 
subpopulation of P. aeruginosa at our institution was first determined, and then we 
started to answer why some agents were more active than others. P. aeruginosa utilize a 
vast variety of mechanisms of resistance to both maintain a high level of inherent 
resistance as well as develop and acquire resistance. Three of the four types of 
mechanisms of resistance were tested: efflux transport system production, porin channel 
inactivation, and degradation enzyme production. RND efflux pump systems are the most 
common types of efflux pumps utilized by P. aeruginosa, so the inhibitor PAβN was 
used to detect the presence of three subtypes of RND pumps: MexAB-OprM, MexCD-
OprJ, and MexEF-OprN. An isolate was positive for any of these efflux pump systems if 
the MIC of cefepime or meropenem decreased at least 2-fold when combined with PAβN. 
A common porin channel of P. aeruginosa is the OprD subtype. In order to build 
resistance, P. aeruginosa will to varying degrees stop production of these channels to 
prevent antimicrobial agents from entering the cell. L-arginine is a substrate of OprD. An 
isolate was considered positive for decreased production of OprD porin channels if the 
MIC of imipenem or meropenem did not change when combined with L-arginine. 
Finally, three different types of beta-lactamases were tested: AmpC, KPC, and MBL. 
Cloxacillin is an inhibitor of AmpC-beta-lactamases. When cloxacillin was combined 
with imipenem or meropenem, if the MIC decreased at least 2-fold, then the isolate was 
considered positive for AmpC-beta-lactamase production. An isolate was considered 
positive for KPC production if the zone of inhibition of imipenem combined with PBA, 
an inhibitor of KPC and AmpC, was at least 5 mm more than the zone of inhibition of 
imipenem alone and the AmpC detection test using cloxacillin was negative. EDTA is a 
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known inhibitor of MBL enzymes. When EDTA was combined with imipenem, if the 
zone of inhibition increased by at least 8 mm compared to imipenem alone then the 
isolate was considered positive for MBL production. The change in MIC for each 
inhibitor (PAβN, cloxacillin, and L-arginine) is provided in Appendix Table 7 and each 
mechanism of resistance utilized by each isolate is provided in Appendix Table 8.  
The most common mechanism of resistance utilized was AmpC-beta-lactamase 
expression at 96% of isolates followed by OprD porin channel down regulation and 
efflux pump system expression at 85% and 83%, respectively (Table 8). Most isolates 
utilized at least three mechanisms of resistance at 73% of isolates utilizing three or four 
of the mechanisms of resistance tested (Figure 19). The most common combination of 
mechanisms of resistance was 64.5% of isolates utilized AmpC-beta-lactamases, RND 
efflux pump systems, and OprD porin channel downregulation (Table 9). Of the isolates 
that expressed this combination of mechanisms of resistance (n=31), 93.5% were 
susceptible to ceftolozane-tazobactam and ceftazidime-avibactam, while 32% were 
susceptible to aztreonam-avibactam. The 6.5% of isolates non-susceptible to ceftolozane-
tazobactam were susceptible to ceftazidime-avibactam and vice versa. Finally, both 
isolates that expressed all mechanisms of resistance tested were susceptible to 
ceftolozane-tazobactam, one isolate was susceptible to ceftazidime-avibactam, and 
neither isolate was susceptible to aztreonam-avibactam.  
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Table 8: Overall Mechanisms of Resistance Phenotypic Expression in XDR-P. 
aeruginosa (n=48) 
Mechanisms of Resistance Isolates (%) 
AmpC-𝝱-Lactamase 96 
OprD Porin Channel 85 
RND Efflux Pump Systems 83 
Metallo-𝝱-Lactamase 6 
K. pneumoniae Carbapenemase 2 
 
 
 
 
Table 9: Combinations of Mechanisms of Resistance Phenotypic Expression of XDR-P. 
aeruginosa (n=48) 
Mechanisms of Resistance Combinations Isolates (%) 
AmpC + RND Efflux Pump Systems + OprD Downregulation 64.5 
AmpC + OprD Downregulation 12.5 
AmpC + RND Efflux Pump Systems 10 
AmpC + RND Efflux Pump Systems + OprD Downregulation + MBL 4 
AmpC 4 
RND Efflux Pump Systems + OprD Downregulation + KPC 2 
RND Efflux Pump Systems + OprD Downregulation + MBL 2 
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Figure 19: Number of Mechanisms of Resistance Utilized by XDR-P. aeruginosa (n=48)  
(MOR=mechanism of resistance) 
 
 
 
 
 
These XDR-P. aeruginosa isolates have a complicated interplay of mechanisms 
of resistance that make them very threatening organisms. The majority of isolates 
expressed multiple mechanisms of resistance, and not every mechanism of resistance was 
able to be tested. There are still mechanisms at work that have yet to be detected. Even 
though these organisms have quite a repertoire of defenses, either ceftolozane-
tazobactam, ceftazidime-avibactam, or aztreonam-avibactam were active against them. 
Not one isolate was non-susceptible to all antimicrobial agents tested. 
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CHAPTER 4. DISCUSSION AND CONCLUSION 
Antimicrobial resistance is a global concern. The Centers for Disease Control and 
Prevention, World Health Organization, and INFORM group have all addressed the 
severity of this issue. The Centers for Disease Control and Prevention estimates that there 
are three million infections in the United States annually caused by resistant 
organisms(2). One of the dangerous organisms is P. aeruginosa. The World Health 
Organization considers the carbapenem resistant P. aeruginosa the second most 
worrisome organisms and highest priority to combat over all other organisms through 
research and development initiatives(4). These isolates are concerning because of their 
diversity of mechanisms of resistance both inherently expressed and acquired. This 
diversity has also made it difficult to build surveillance data and develop resistance 
patterns(2). An understanding of just how complicated and threatening these organisms 
are is limited at this time. 
P. aeruginosa have high inter-institutional variability and the population of P. 
aeruginosa at the University of Kentucky HealthCare had yet to be characterized. There 
have been about 5,000 P. aeruginosa isolates seen at the University of Kentucky 
HealthCare over the past ten years. Of these isolates, 20% were considered MDR-P. 
aeruginosa and 7% XDR-P. aeruginosa. Isolates were labeled multidrug-resistant if they 
were non-susceptible to at least one agent from at least three antipseudomonal agent 
categories, and extensively drug-resistant if they were non-susceptible to at least one 
agent from all but two or less of the antipseudomonal agent categories. The rate of XDR-
P. aeruginosa isolates at our institution was similar to the national average of 9%(5). 
64 
 
Even though a rate that is less than 10% seems low and less concerning, these isolates are 
very concerning because they were more likely to not receive appropriate empiric therapy 
which led to worse patient outcomes and higher mortality(8). The activity of new 
antipseudomonal agents intended for the treatment of resistant infections and what 
patterns of resistance mechanisms utilized at the University of Kentucky HealthCare was 
unknown. Through in vitro analysis of our XDR-P. aeruginosa population, the 
foundation of our understanding of these complicated organisms was built in order to 
start improving empiric therapy selection to improve patient outcomes, decrease 
mortality, and start to combat the problem these organisms create at our institution. 
Broth microdilution is the gold standard in vitro susceptibility test. Broth 
microdilution was utilized to confirm the susceptibility results generated by BD 
Phoenix™ Automated System at the University of Kentucky HealthCare Clinical 
Microbiology Laboratory of common antipseudomonal agents utilized at our institution, 
and to determine susceptibilities of agents not included on their panel. All agents tested in 
duplicate on at least two separate occasions included gentamicin, tobramycin, amikacin, 
levofloxacin, meropenem, imipenem, piperacillin-tazobactam, cefepime, ceftazidime, 
aztreonam, colistin, polymyxin B, ceftazidime-avibactam, aztreonam-avibactam, and 
ceftolozane-tazobactam (Etest®). The 48 XDR-P. aeruginosa isolates tested were 
selected based on BD Phoenix™ generated non-susceptibility to gentamicin, tobramycin, 
meropenem, piperacillin-tazobactam, cefepime, ceftazidime, aztreonam, levofloxacin, 
and ciprofloxacin. 
Against extensively drug-resistant isolates from our academic medical center, 
colistin and polymyxin B both had 100% susceptibility. Both ceftolozane-tazobactam and 
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ceftazidime-avibactam exhibited great activity with the next highest susceptibilities at 
94% and 90% of isolates, respectively. Both agents restored in vitro susceptibility while 
aztreonam-avibactam had poor activity at 40% of isolates susceptible. The addition of 
avibactam did not restore the activity of aztreonam. Ceftolozane-tazobactam non-
significantly demonstrated greater susceptibility and potency than ceftazidime-avibactam; 
confirming surveillance data produced by multicenter studies. One multicenter in vitro 
study in the United States compared the activity of ceftazidime-avibactam and 
ceftolozane-tazobactam in 290 meropenem non-susceptible P. aeruginosa isolates from 
2013 to 2014. Ceftolozane-tazobactam was more potent than ceftazidime-avibactam and 
91% of isolates were susceptible to ceftolozane-tazobactam compared to 81% of isolates 
were susceptible to ceftazidime-avibactam(32).  
A second comparator study investigated the susceptibility of P. aeruginosa 
isolates (n=1,909) in the INFORM surveillance program to ceftolozane-tazobactam and 
ceftazidime-avibactam. Of all isolates, 96.9% and 97.5% were susceptible to ceftazidime-
avibactam and ceftolozane-tazobactam, respectively. However, when isolates non-
susceptible to ceftazidime, cefepime, piperacillin-tazobactam, and meropenem (n=161) 
were selected, ceftolozane-tazobactam and ceftazidime-avibactam activity both greatly 
decreased. Even though ceftolozane-tazobactam maintained greater susceptibility than 
ceftazidime-avibactam, only 78.7% and 70.2% of isolates were susceptible to 
ceftolozane-tazobactam and ceftazidime-avibactam, respectively(33). One final, and most 
recent, comparator study evaluated the 2017-2018 INFORM census. They assessed the 
activity of ceftolozane-tazobactam and ceftazidime-avibactam in isolates from 
pneumonia patients at United States medical centers that were non-susceptible to 
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meropenem, piperacillin-tazobactam, and ceftazidime. Even though these isolates were 
also not considered extensively drug-resistant, ceftolozane-tazobactam and ceftazidime-
avibactam again had less activity compared to our extensively drug-resistant isolates. 
Only 73.7%  of isolates were susceptible to ceftolozane-tazobactam and 73% of isolates 
susceptible to ceftazidime-avibactam(48). These lower susceptibilities do not encourage 
confident recommendations of use in suspected resistant infections. Our study’s 
confirmatory results with much higher susceptibilities of both agents suggests empiric 
use of ceftolozane-tazobactam against serious intra-abdominal infections, pneumonia, or 
urinary tract infections presenting to our institution because of its high potency compared 
to ceftazidime-avibactam. However, it was unclear why our XDR-P. aeruginosa 
population had much higher susceptibility to both ceftolozane-tazobactam and 
ceftazidime-avibactam compared to these other surveillance studies, especially since 
baseline susceptibility to standard of care agents is significantly lower. It was also unclear 
if there are times when, or other institutions where, ceftazidime-avibactam would be the 
preferred agent. Because these agents target different mechanisms of resistance, an 
analysis of the mechanisms of resistance at play helped answer these questions. 
There are four general types of mechanisms of resistance utilized by microbial 
organisms. These include efflux pump transport systems, porin channel inactivation, 
enzyme degradation, and target site modifications. The latter method is less common in 
P. aeruginosa compared to the first three listed. Of the many types of efflux transport 
systems, P. aeruginosa primarily produce RND efflux systems including MexAB-OprM, 
MexCD-OprJ, MexEF-OprN, and MexXY-OprM(10). To phenotypically detect the 
presence of all these efflux systems except MexXY-OprM, the broad-spectrum efflux 
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pump inhibitor PAβN was utilized. MexXY-OprM differs from other RND pumps in that 
it is an inducible pump rather than an intrinsic efflux pump system. It could not be 
detected with an inhibitor like PAβN, but rather first an inciting event such as oxidative 
stress through hydrogen peroxide exposure or exposure to antimicrobial agents that target 
the ribosome to induce its overproduction is required, and then the change in MIC of 
antimicrobial substrates such as cefepime or aminoglycosides can be tested(49). The MIC 
of efflux substrates meropenem and cefepime were compared when combined with 
PAβN and alone(10,13). An isolate was considered positive for efflux pump phenotypic 
expression and production if the MIC of meropenem or cefepime decreased at least 2-
fold in the presence of PAβN(14,15). P. aeruginosa do not rely on one mechanism of 
resistance and usually create a network of mechanisms. Another common piece to their 
network is porin channel manipulation. For example, frequently the OprD porin channel 
will be downregulated while the MexAB-OprM system overproduced creating 
carbapenem resistance(5,11,12). To detect the presence of the OprD porin channel 
changes, the MIC of OprD substrates imipenem and meropenem was analyzed when in 
the presence of the competing substrate L-arginine. If an isolate has inactivated their 
OprD porin channels, then the MIC of imipenem or meropenem did not change when 
combined with L-arginine(15). 
To assess the presence of enzyme production various inhibitors were utilized. The 
three enzymes detected were AmpC-beta-lactamases, KPC, and MBL carbapenemases. 
Even though AmpC enzymes do not independently cause carbapenem resistance, when 
they are active with an efflux pump or porin channel downregulation as a part of this 
resistance network carbapenem resistance can result(18). Both cloxacillin and PBA are 
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inhibitors of AmpC-beta-lactamases. The combination of cloxacillin and imipenem or 
meropenem was the primary test for AmpC presence. When the MIC of imipenem or 
meropenem decreased at least 2-fold in the presence of cloxacillin then the isolate was 
considered positive for AmpC-beta-lactamase production or hyperproduction(14,44,45). 
While KPC enzymes are more frequently seen in other gram-negative organisms they can 
be acquired by P. aeruginosa(19). As mentioned, PBA is a known inhibitor of KPC. The 
zone of inhibition of imipenem increased by at least 5 mm for an isolate to be considered 
positive for either KPC or AmpC(22). An isolate was positive for KPC if it was 
considered negative for AmpC production when tested with cloxacillin. EDTA is a 
chelating agent, so it is an inhibitor of MBL carbapenemases. MBL enzymes are the most 
common carbapenemases in P. aeruginosa(12). If the zone of inhibition of imipenem 
increased by at least 8 mm in the presence of EDTA, then the isolate was considered 
positive for MBL production(23).   
There was high detection of AmpC-beta-lactamase expression, OprD 
downregulation, and efflux pump system expression compared to carbapenemase 
detection by the XDR-P. aeruginosa seen at our institution. AmpC-beta-lactamases were 
produced by almost all isolates (96%). OprD porin channel inactivation and efflux pump 
transport system production were not far behind at 85% and 83% of isolates, respectively, 
while KPC and MBL presence were minimal at 2% and 6%, respectively. Further, the 
most common combination of mechanisms was 64.5% of isolates had created a network 
of AmpC-beta-lactamases, OprD porin channel manipulation, and efflux pump system 
production. This confirmed the ceftolozane-tazobactam preference in our population of 
XDR-P. aeruginosa. Ceftazidime-avibactam is only protected against AmpC-beta-
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lactamases and carbapenemases such as KPC, while ceftolozane-tazobactam has 
protection from OprD porin channel downregulation, efflux pump system production, and 
AmpC-beta-lactamases(26).  The frequent reliance on OprD porin channel inactivation 
and RND efflux transport systems within the resistance network also confirmed the poor 
activity of aztreonam-avibactam even in isolates that were also MBL-positive. Because 
P. aeruginosa typically rely on multiple mechanisms of resistance, not just enzyme 
degradation, aztreonam-avibactam did not have promising outcomes in surveillance 
studies nor our population study(37,38). 
While this study provides a foundation for future testing of XDR-P. aeruginosa at 
our institution, there are some limitations of the phenotypic expression model and 
susceptibility testing to consider. The primary limitations of the phenotypic model 
included results were not confirmed with genotypic expression testing, and the expected 
changes in MIC were narrow. The acceptable change was within the standard of error for 
broth microdilution. Testing was completed in duplicate on at least two separate 
occasions to minimize error due to a small change in MIC. Further, there is a high 
variability between P. aeruginosa isolates, so phenotypic surveillance studies are limited 
for comparison, and confirmation of results with other studies is difficult. The phenotypic 
expression analysis also qualitatively shows the presence of resistance mechanisms but 
cannot quantitatively show to what extent it is utilized and the bacteria’s dependence. For 
example, the two isolates expressing all mechanisms of resistance tested were susceptible 
to ceftolozane-tazobactam and not aztreonam-avibactam. It could be inferred that while 
MBL enzymes are present they may not be utilized to the same extent as the other 
mechanisms of resistance. This would allow ceftolozane-tazobactam enough activity 
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prior to enzyme degradation by the MBL. This inference requires further quantitative 
analysis for validation. Finally, not all mechanisms were evaluated. Even though many of 
the most common components of the network of mechanisms utilized by P. aeruginosa 
were tested, there are still gaps in developing our population’s resistance pattern. For 
example, two isolates tested were only positive for AmpC-beta-lactamase production. An 
isolate cannot be carbapenem-resistant only using AmpC-beta-lactamases, so there must 
be other mechanisms at work that we have yet to detect. While phenotypic expression 
models are limited, they provide a baseline characterization of the population of XDR-P. 
aeruginosa seen at our institution and provide foundational insights for clinical study 
development. 
In vitro susceptibility testing also has some limitations. In vitro testing does not 
allow for analysis of other factors that affect antimicrobial agent activity and bacterial 
killing. For example, the role of the patient’s immune system is not included. Further, 
broth microdilution only allows for antimicrobial susceptibility to be analyzed at a single 
point in time rather than analysis of the growth or killing trends overtime. Susceptibility 
can be affected by the extent of antimicrobial exposure. Other more dynamic in vitro and 
in vivo models such as time-kills and murine models are needed prior to definitively 
recommending ceftolozane-tazobactam or ceftazidime-avibactam as empiric 
monotherapy of suspected resistant P. aeruginosa infections at our institution. Finally, 
access to ceftolozane powder was restricted and only ceftolozane-tazobactam Etest® 
strips where available for use. Different procedural errors may occur during either broth 
microdilution or Etest® protocols; therefore, an error may have affected ceftolozane-
tazobactam’s susceptibility profile and not ceftazidime-avibactam’s profile or vice versa. 
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Testing was completed in duplicate on at least two separate occasions to minimize the 
effect of this potential error. Further, all susceptibility testing was performed on the 
quality control organism P. aeruginosa ATCC 27853 to confirm the appropriate activity 
of each antimicrobial agent. Even though there are limitations, our susceptibility results 
confirmed general surveillance studies of these new beta-lactam/beta-lactamase inhibitor 
agents, allowing our in vitro analysis to provide a foundation for further analysis of the 
whole population of XDR-P. aeruginosa seen at our institution.  
Moving forward there are numerous directions and follow-up studies that can be 
undertaken and completed in order to grow in our understanding of XDR-P. aeruginosa 
at our institution and continue to combat the imminent problem they create. This was the 
first study looking at these P. aeruginosa isolates at the University of Kentucky 
HealthCare, so there is still so much that is unknown. One direction would be to expand 
on what is now known about these 48 XDR-P. aeruginosa isolates. Investigating the in 
vitro activity of the other new antipseudomonal agents including cefiderocol, cefepime-
zidebactam, and imipenem-relebactam would be an interesting comparison and would 
expand our options for treating these isolates that historically substantially limit our 
options. There are also some mechanisms of resistance in these isolates that have been 
left undetected. These include the MexXY-OprM efflux pump system, other porin 
channels, enzymes, and target site alterations like penicillin-binding-protein changes. 
Further, combining different inhibitors such as PAβN and cloxacillin would show how 
much improvement in MIC could result through combating more than one mechanism at 
once. This will start to quantify improvement. This will also help determine if there is 
compensation and to what extent by the other mechanisms if one is inhibited. Finally, the 
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effect these inhibitors alone and in combination have overtime can be assessed through in 
vitro time-kill experimentation. All this testing as well as what has been completed can 
be expanded and assessed in the remaining 34 XDR-P. aeruginosa isolates as well as 
isolates since received from the University of Kentucky HealthCare Clinical 
Microbiology Laboratory and yet to be characterized. Once the population of the 
University of Kentucky has been fully characterized, it can then be expanded to 
incorporate other institutions across Kentucky to start to characterize the state and region 
as a whole.  
XDR-P. aeruginosa are complicated organisms with extensive networks of 
resistance. The high inter-institutional variability in these developed networks poses a 
greater threat because they cannot be combated as a whole through global surveillance 
studies and initiatives. There is a burden that falls on each institution to characterize their 
population of XDR-P. aeruginosa in order to take the best proactive and reactive 
measures. The University of Kentucky HealthCare XDR-P. aeruginosa population relies 
on many mechanisms of resistances, with AmpC-beta-lactamase expression, OrpD porin 
channel inactivation, and RND efflux transport pump system expression being the most 
frequently detected. This baseline understanding of these organisms builds confidence in 
the susceptibility results favoring the use of ceftolozane-tazobactam in these isolates. 
This study provides promising results that if confirmed with further dynamic in vitro and 
in vivo models, can lead to more optimized clinical recommendations in best use of new 
agents like ceftolozane-tazobactam in P. aeruginosa causing infections. This will help 
improve patient outcomes and prevent development of greater resistance by these 
dangerous organisms through minimizing inappropriate use of these antimicrobial agents.
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APPENDIX. SUPPLEMENTAL TABLES  
Table A1: MIC (µg/ml) and Susceptibility Category of Each Antimicrobial Agent Against Each P. aeruginosa 
Isolate (n=287) Determined By BD Phoenix™ Automated Systems at the University of Kentucky HealthCare 
Clinical Microbiology Laboratory (S=susceptible; I=intermediate; R=resistant; yellow=MDR; green=XDR; 
*=XDR isolates evaluated) 
Isolate Ceftazidime Piperacillin-
Tazobactam 
Levofloxacin Ciprofloxacin Aztreonam 
56 >16 R >64/4 R >4 R >2 R 16 I 
57 >16 R >64/4 R >4 R >2 R >16 R 
62 4 S 32/4 I >4 R >2 R 16 I 
68 16 I 64/4 I 2 S 2 I >16 R 
74 >16 R 64/4 I >4 R >2 R >16 R 
80 >16 R >64/4 R >4 R >2 R >16 R 
82 >16 R >64/4 R >4 R >2 R 8 S 
88* >16 R >64/4 R >4 R >2 R 16 I 
100 >16 R >64/4 R <=1 S <=0.5 S >16 R 
108 16 I 64/4 I >4 R >2 R 16 I 
109 8 S 32/4 I >4 R >2 R 16 I 
110 >16 R >64/4 R -- -- >2 R >16 R 
133 >16 R 32/4 I >4 R >2 R >16 R 
153 -- -- -- R -- R -- -- -- R 
157* >16 R 64/4 I >4 R >2 R >16 R 
161 4 S 16/4 S >4 R >2 R >16 R 
181 4 S 32/4 I >4 R >2 R >16 R 
182 16 I 64/4 I >4 R >2 R >16 R 
183 8 S 32/4 I >4 R >2 R 16 I 
184* >16 R >64/4 R >4 R >2 R >16 R 
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192 >16 R >64/4 R >4 R >2 R 16 I 
199 >16 R 64/4 I >4 R >2 R >16 R 
202 >16 R 64/4 I <=1 S <=0.5 S >16 R 
205 8 S 32/4 I >4 R 2 I >16 R 
207 8 S 16/4 S >4 R >2 R >16 R 
208* 16 I >64/4 R >4 R >2 R 16 I 
211* >16 R >64/4 R >4 R >2 R 16 I 
218 >16 R >64/4 R >4 R >2 R 16 I 
220 8 S >64/4 R 4 I >2 R 8 S 
221 16 I 64/4 I >4 R >2 R >16 R 
222 >16 R >64/4 R 4 I 2 I >16 R 
224 16 I 32/4 I >4 R >2 R >16 R 
228 16 I 64/4 I >4 R >2 R 16 I 
229 8 S 32/4 I >4 R >2 R >16 R 
231 16 I 64/4 I >4 R >2 R >16 R 
234* >16 R >64/4 R >4 R >2 R 16 I 
236 8 S 32/4 I >4 R >2 R >16 R 
247 16 I 32/4 I >4 R >2 R >16 R 
249 >16 R >64/4 R >4 R >2 R >16 R 
251* 16 I 64/4 I >4 R >2 R 16 I 
252 16 I >64/4 R >4 R >2 R >16 R 
254 16 I >64/4 R >4 R >2 R 16 I 
259* >16 R >64/4 R >4 R >2 R >16 R 
265 >16 R >64/4 R >4 R >2 R >16 R 
270 16 I 32/4 I 4 I 1 S >16 R 
273 8 S 32/4 I 4 I 2 I >16 R 
275 16 I 32/4 I 4 I 2 I >16 R 
279* 16 I >64/4 R >4 R >2 R >16 R 
282 8 S 64/4 I >4 R >2 R >16 R 
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286 16 I 64/4 I >4 R >2 R >16 R 
295 4 S 16/4 S >4 R 2 I >16 R 
297* 16 I >64/4 R >4 R >2 R >16 R 
298 8 S 64/4 I >4 R >2 R >16 R 
300* 16 I >64/4 R >4 R >2 R >16 R 
305 >16 R >64/4 R >4 R >2 R >16 R 
313* 16 I >64/4 R >4 R >2 R >16 R 
316 16 I 64/4 I >4 R >2 R 16 I 
322 16 I 64/4 I >4 R >2 R 16 I 
323 16 I 32/4 I >4 R >2 R >16 R 
326* >16 R >64/4 R >4 R >2 R >16 R 
327* 16 I 64/4 I >4 R >2 R 16 I 
329 8 S 32/4 I >4 R >2 R >16 R 
332 8 S >64/4 R >4 R >2 R >16 R 
336 8 S 32/4 I 2 S 1 S >16 R 
337* >16 R 64/4 I >4 R >2 R >16 R 
338* >16 R >64/4 R >4 R >2 R 16 I 
345 8 S 32/4 I >4 R >2 R >16 R 
346* >16 R 64/4 I >4 R >2 R >16 R 
351 >16 R >64/4 R >4 R >2 R >16 R 
356 8 S 32/4 I 4 I 2 I >16 R 
359 >16 R >64/4 R 4 I 2 I >16 R 
360* >16 R >64/4 R >4 R >2 R >16 R 
363* >16 R 32/4 I >4 R >2 R >16 R 
364 8 S 32/4 I 4 I 1 S >16 R 
365 >16 R 32/4 I >4 R >2 R >16 R 
366 >16 R >64/4 R >4 R >2 R 16 I 
377 >16 R >64/4 R >4 R >2 R >16 R 
378 16 I >64/4 R >4 R >2 R 16 I 
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380 8 S 32/4 I >4 R >2 R >16 R 
381* >16 R >64/4 R >4 R >2 R >16 R 
394 16 I >64/4 R >4 R >2 R >16 R 
396 >16 R >64/4 R >4 R >2 R 16 I 
397 >16 R >64/4 R >4 R >2 R >16 R 
399 >16 R >64/4 R 2 S 1 S >16 R 
404 >16 R >64/4 R 4 I >2 R >16 R 
415 8 S 32/4 I >4 R >2 R >16 R 
424 16 I >64/4 R >4 R >2 R 16 I 
427 >16 R >64/4 R >4 R >2 R >16 R 
428 >16 R >64/4 R >4 R >2 R >16 R 
429 16 I 64/4 I >4 R >2 R >16 R 
430 >16 R >64/4 R >4 R >2 R >16 R 
436* >16 R >64/4 R >4 R >2 R 16 I 
437* >16 R >64/4 R >4 R >2 R >16 R 
447 8 S 32/4 I 4 I 1 S >16 R 
448 >16 R 8/4 S 4 I >2 R 8 S 
450 >16 R >64/4 R >4 R >2 R >16 R 
451 16 I 32/4 I 4 I 1 S >16 R 
455 >16 R <=2/4 S 4 I >2 R >16 R 
464 >16 R >64/4 R >4 R >2 R >16 R 
471 >16 R >64/4 R >4 R >2 R >16 R 
473 >16 R 64/4 I >4 R >2 R >16 R 
483 >16 R >64/4 R >4 R >2 R >16 R 
487 >16 R >64/4 R >4 R >2 R >16 R 
489* >16 R >64/4 R >4 R >2 R >16 R 
490 8 S 32/4 I >4 R >2 R >16 R 
491 8 S 32/4 I 4 I 2 I >16 R 
494 8 S 32/4 I >4 R >2 R >16 R 
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497* >16 R 64/4 I >4 R >2 R >16 R 
498* >16 R >64/4 R >4 R >2 R >16 R 
499 16 I 32/4 I 4 I 1 S >16 R 
500 >16 R 64/4 I <=1 S <=0.5 S >16 R 
504 >16 R >64/4 R 4 I 2 I >16 R 
505 16 I 32/4 I >4 R >2 R >16 R 
509 16 I 32/4 I >4 R >2 R >16 R 
511 16 I 32/4 I >4 R >2 R 16 I 
518 8 S 32/4 I >4 R >2 R >16 R 
519 16 I >64/4 R >4 R >2 R 16 I 
520 16 I 32/4 I 2 S <=0.5 S >16 R 
523 6 I -- -- >32 R -- -- 2 S 
524 8 S 16/4 S >4 R >2 R >16 R 
525 8 S 32/4 I >4 R >2 R >16 R 
526 16 I 64/4 I >4 R >2 R >16 R 
527 >16 R >'64/4 R >4 R >2 R >16 R 
529 >16 R >64/4 R >4 R >2 R >16 R 
530 8 S 32/4 I >4 R >2 R >16 R 
531 8 S 32/4 I >4 R >2 R >16 R 
532 16 I 32/4 I >4 R >2 R >16 R 
533 8 S 32/4 I >4 R >2 R >16 R 
535* 16 I >64/4 R >4 R >2 R 16 I 
540 16 I 32/4 I >4 R >2 R >16 R 
543 8 S -- -- >4 R >2 R >16 R 
P. aeruginosa Collection 
1 2 S 16/4 S <=1 S <=0.5 S 16 I 
2 2 S 32/4 I 4 I 1 S >16 R 
3 8 S 32/4 I >4 R >2 R 16 I 
4 4 S 32/4 I >4 R >2 R >16 R 
  
78 
Table A1 (continued) 
5 8 S 16/4 S >4 R >2 R >16 R 
6 4 S 8/4 S <=1 S <=0.5 S 8 S 
7 4 S >64/4 R >4 R >2 R >16 R 
8 8 S 32/4 I >4 R >2 R 16 I 
9 1 S 4/4 S <=1 S <=0.5 S 8 S 
11 2 S 4/4 S <=1 S <=0.5 S 8 S 
12* 16 I 64/4 I >4 R >2 R >16 R 
13 2 S 4/4 S <=1 S <=0.5 S 8 S 
14 4 S 32/4 I >4 R >2 R 8 S 
15 4 S 16/4 S <=1 S <=0.5 S 16 I 
16 16 I 16/4 S >4 R >2 R >16 R 
17* >16 R >64/4 R >4 R 2 I >16 R 
18 4 S 16/4 S 2 S 1 S >16 R 
19 2 S 8/4 S <=2 S <=0.5 S 8 S 
20 1 S 4/4 S <=1 S <=0.5 S 4 S 
21 4 S 8/4 S >4 R >2 R 4 S 
22 2 S 4/4 S <=1 S <=0.5 S 8 S 
23 4 S 4/4 S <=1 S <=0.5 S 8 S 
24* >16 R 64/4 I >4 R >2 R 16 I 
25 2 S 4/4 S <=1 S <=0.5 S 4 S 
26 2 S 4/4 S <=1 S <=0.5 S 8 S 
27 <=0.5 S <=2/4 S 4 I 2 I <=2 S 
28* >16 R >64/4 R >4 R >2 R >16 R 
29* 16 I 64/4 I >4 R >2 R >16 R 
30 2 S 4/4 S <=1 S <=0.5 S 8 S 
31 1 S 4/4 S <=1 S <=0.5 S 8 S 
32 2 S 8/4 S <=1 S <=0.5 S 8 S 
33 8 S 32/4 I 4 I 2 I >16 R 
34 16 I 64/4 I 4 I 2 I >16 R 
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35 16 I 4/4 S 4 I >2 R >16 R 
36* >16 R 64/4 I >4 R >2 R 16 I 
37 4 S 16/4 S >4 R >2 R >16 R 
38 1 S 1 S 2 S -- -- 1 S 
39 -- -- 0.75 S 0.125 S -- -- 1 S 
40 -- -- 24 I >32 R -- -- 12 I 
41 1.5 S 1.5 S 6 R -- -- 1 S 
42 0.38 S 0.125 S 4 I -- -- 0.125 S 
43 1 S 4/4 S <=1 S <=0.5 S 4 S 
44 8 S 32/4 I >4 R >2 R 8 S 
45 16 I 64/4 I >4 R >2 R 8 S 
46 2 S 8/4 S <=1 S <=0.5 S 8 S 
47* >16 R >64/4 R >4 R >2 R >16 R 
48 -- -- 32 I >=32 R -- -- 24 R 
49 2 S 8/4 S <=1 S <=0.5 S 8 S 
50 2 S 4/4 S <=1 S <=0.5 S 8 S 
51 8 S 32/4 I 4 I 2 I >16 R 
52 16 I >256 R 8 R -- -- 12 I 
53 8 S 16/4 S >4 R >2 R >16 R 
54 2 S 4/4 S <=1 S <=0.5 S 8 S 
55 2 S 4/4 S <=1 S <=0.5 S 8 S 
56 4 S 8/4 S <=1 S <=0.5 S 8 S 
57 8 S 16/4 S >4 R >2 R 8 S 
58 2 S 8/4 S >4 R >2 R 8 S 
59 2 S <=2/4 S <=1 S <=0.5 S 4 S 
60 4 S 4/4 S <=1 S <=0.5 S 8 S 
61* 16 I 64/4 I >4 R >2 R 16 I 
62 2 S 4/4 S <=1 S <=0.5 S 8 S 
63 8 S 32/4 I 2 S 1 S >16 R 
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65 -- -- 48/4 I >32 R -- -- >256 R 
66* >16 R 32/4 I >4 R >2 R >16 R 
67 4 S 32/4 I >4 R >2 R 8 S 
68 >256 R >256/4 R >32 R -- -- >256 R 
69 2 S 8/4 S <=1 S <=0.5 S 8 S 
70 <=0.5 S <=2/4 S 2 S 1 S <=2 S 
71 4 S 16/4 S 4 I 1 S >16 R 
72 8 S 8/4 S >4 R >2 R 8 S 
73 >16 R >64/4 R >4 R >2 R >16 R 
74 >16 R 64/4 I >4 R >2 R 16 I 
75 8 S 64/4 I >4 R >2 R >16 R 
76 4 S 16/4 S 4 I 1 S >16 R 
77 8 S 32/4 I >4 R >2 R >16 R 
78 4 S 8/4 S >4 R >2 R -- -- 
79 4 S 4/4 S <=1 S <=0.5 S 8 S 
80 2 S 4/4 S <=1 S <=0.5 S 8 S 
81 -- -- 48/4 I >32 R -- -- 12 I 
82 16 I 64/4 I <=1 S <=0.5 S 16 I 
83* >16 R >64/4 R >4 R >2 R 16 I 
84* 16 I 64/4 I >4 R >2 R 16 I 
85* >16 R >64/4 R >4 R >2 R >16 R 
86 4 S 8/4 S <=1 S <=0.5 S 16 I 
87 >16 R >64/4 R 2 S 1 S 16 I 
88 4 S 16/4 S <=1 S <=0.5 S 16 I 
89 8 S 8/4 S >4 R >2 R >16 R 
90 8 S 32/4 I 2 S 1 S >16 R 
91 4 S 16/4 S >4 R >2 R >16 R 
92* >16 R >64/4 R >4 R >2 R >16 R 
93* >16 R >64/4 R >4 R >2 R >16 R 
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94 >16 R >64/4 R >4 R >2 R >16 R 
95 8 S 32/4 I 4 I 1 S >16 R 
96* 16 I >64/4 R >4 R >2 R >16 R 
97 8 S 16/4 S >4 R >2 R 8 S 
98 >16 R >64/4 R <=1 S <=0.5 S 4 S 
99 2 S 4/4 S <=1 S <=0.5 S 4 S 
100 8 S 32/4 I >4 R >2 R 8 S 
101 >16 R 64/4 I <=1 S <=0.5 S 16 I 
102 4 S 32/4 I <4 R >2 R 8 S 
103 8 S 16/4 S 4 I 2 I >16 R 
104 2 S 8/4 S <=1 S <=0.5 S 8 S 
105 >16 R 16/4 S <=1 S <=0.5 S 16 I 
106 16 I 64/4 I <=1 S <=0.5 S 16 I 
107* 15 I >64/4 R >4 R >2 R >16 R 
108 4 S 16/4 S <=1 S <=0.5 S 16 I 
109 8 S 64/4 I <4 R >2 R 8 S 
110 4 S 8/4 S <=1 S <=0.5 S 8 S 
111 4 S 8/4 S >4 R >2 R 8 S 
112 8 S 64/4 I >4 R >2 R 8 S 
113 8 S 32/4 I >4 R >2 R 16 I 
114 16 I 16/4 S <=1 S <=0.5 S 16 I 
115* 16 I >64/4 R >4 R >2 R 16 I 
116 16 I 64/4 I >4 R >2 R 16 I 
117 16 I >64/4 R >4 R >2 R <=2 S 
118 8 S 16/4 S >4 R >2 R >16 R 
119 >16 R >64/4 R 4 I >2 R >16 R 
120 8 S 32/4 I >4 R >2 R 8 S 
121 8 S 32/4 I >4 R >2 R 8 S 
122 4 S 16/4 S <=1 S <=0.5 S 16 I 
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123 >16 R >64/4 R 4 I 2 I >16 R 
124 16 I >64/4 R 4 R >2 R 16 I 
125 16 I 64/4 I <=1 S -- -- -- -- 
126 16 I 32/4 I <=1 S <=0.5 S 4 S 
127 16 I 64/4 I <=1 S <=0.5 S 8 S 
128* 16 I 32/4 I >4 R >2 R 16 I 
129 8 S 64/4 I >4 R >2 R 16 I 
130 2 S 4/4 S <=1 S <=0.5 S 8 S 
131* >16 R 64/4 I >4 R >2 R >16 R 
132 2 S 8/4 S <=1 S <=0.5 S 8 S 
133 8 S 32/4 I >4 R >2 R >16 R 
134 8 S 32/4 I 2 S 1 S >16 R 
135 >16 R 64/4 I >4 R >2 R 16 I 
136* >16 R >64/4 R >4 R >2 R >16 R 
137 8 S 32/4 I >4 R >2 R >16 R 
138 4 S 8/4 S <=1 S <=0.5 S 16 I 
139 16 I 64/4 I >4 R >2 R 8 S 
140 8 S 16/4 S 2 S 1 S >16 R 
141 4 S 8/4 S <=1 S <=0.5 S 16 I 
142 16 I 64/4 I >4 R >2 R 8 S 
143 1 S 4/4 S <=1 S <=0.5 S 4 S 
144* >16 R >64/4 R >4 R >2 R >16 R 
145 >16 R >64/4 R >4 R >2 R >16 R 
146 8 S 64/4 I 4 I 1 S >16 R 
147 16 I >64/4 R >4 R >2 R >16 R 
148 >16 R 32/4 I <=1 S <=0.5 S >16 R 
149 2 S 8/4 S <=1 S <=0.5 S 8 S 
150 2 S 8/4 S <=1 S <=0.5 S 8 S 
151* 16 I >64/4 R >4 R >2 R >16 R 
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152 16 I 64/4 I >4 R >2 R 16 I 
153* 16 I >64/4 R >4 R >2 R >16 R 
154 2 S 8/4 S <=1 S >=0.5 S 8 S 
155 4 S 16/4 S <=1 S <=0.5 S 16 I 
156 4 S 32/4 I 4 I >2 R 16 I 
157 2 S 4/4 S <=1 S <=0.5 S 8 S 
158 16 I 16/4 S >4 R >2 R 16 I 
 
Isolate Gentamicin Tobramycin Amikacin Meropenem Cefepime 
56 >8 R 4 S 32 I <=1 S >16 R 
57 >8 R >8 R <=8 S 4 I >16 R 
62 >8 R >8 R 16 S >8 R 16 I 
68 <=2 S <=2 S <=8 S 8 R 16 I 
74 <=2 S <=2 S <=8 S >8 R >16 R 
80 >8 R >8 R <=8 S <=1 S 16 I 
82 >8 R >8 R <=8 S 8 R 16 I 
88* >8 R >8 R <=8 S >8 R >16 R 
100 <=2 S <=2 S <=8 S 8 R 16 I 
108 >8 R >8 R >32 R <=1 S 16 I 
109 >8 R >8 R <=8 S >8 R 16 I 
110 <=2 S <=2 S <=8 S 2 S >16 R 
133 >8 R >8 R >32 R >8 R >16 R 
153 R R R R R R R R R R 
157* >8 R >8 R <=8 S >8 R >16 R 
161 <=2 S <=2 S <=8 S >8 R >16 R 
181 4 S <=2 S <=8 S >8 R 16 I 
182 4 S <=2 S <=8 S 8 R 8 S 
183 >8 R >8 R <=8 S 8 R 16 I 
184* >8 R >8 R <=8 S >8 R 16 I 
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192 >8 R >8 R <=8 S 2 S 16 I 
199 <=2 S <=2 S <=8 S >8 R >16 R 
202 <=2 S <=2 S <=8 S 8 R 16 I 
205 <=2 S <=2 S <=8 S <=1 S 16 I 
207 <=2 S <=2 S <=8 S >8 R 16 I 
208* >8 R >8 R <=8 S >8 R 16 I 
211* >8 R 8 I <=8 S 8 R 16 I 
218 8 I <=2 S <=8 S 8 R 16 I 
220 >8 R >8 R <=8 S >8 R 16 I 
221 8 I 4 S 32 I >8 R >16 R 
222 <=2 S <=2 S <=8 S 2 S 16 I 
224 4 S <=2 S <=8 S >8 R 16 I 
228 >8 R >8 R <=8 S 4 I 16 I 
229 <=2 S <=2 S <=8 S 4 I 8 S 
231 <=2 S <=2 S <=8 S >8 R 16 I 
234* >8 R >8 R <=8 S >8 R 16 I 
236 <=2 S <=2 S <=8 S >8 R 8 S 
247 4 S <=2 S <=8 S >8 R >16 R 
249 8 I <=2 S <=8 S >8 R >16 R 
251* >8 R >8 R <=8 S 8 R 16 I 
252 >8 R >8 R >32 R 2 S 16 I 
254 >8 R >8 R <=8 S 4 I 16 I 
259* >8 R >8 R <=8 S >8 R >16 R 
265 <=2 S <=2 S <=8 S 2 S 16 I 
270 <=2 S <=2 S <=8 S 2 S 16 I 
273 4 S <=2 S <=8 S 2 S 16 I 
275 4 S <=2 S <=8 S 1 S 16 I 
279* >8 R >8 R <=8 S >8 R 16 I 
282 >8 R >8 R <=8 S >8 R 16 I 
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286 <=2 S <=2 S <=8 S >8 R 16 I 
295 <=2 S <=2 S <=8 S >8 R 16 I 
297* >8 R >8 R <=8 S >8 R >16 R 
298 >8 R >8 R <=8 S >8 R 16 I 
300* >8 R >8 R <=8 S >8 R >16 R 
305 >8 R >8 R <=8 S 4 I 16 I 
313* >8 R >8 R <=8 S >8 R >16 R 
316 >8 R >8 R <=8 S 4 I 16 I 
322 >8 R >8 R <=8 S 8 R 8 S 
323 >8 R >8 R 16 S 8 R >16 R 
326* >8 R >8 R <=8 S >8 R >16 R 
327* >8 R >8 R <=8 S 8 R 16 I 
329 <=2 S <=2 S <=8 S >8 R 16 I 
332 >8 R >8 R <=8 S >8 R 16 I 
336 4 S <=2 S <=8 S >8 R 16 I 
337* >8 R >8 R <=8 S >8 R 16 I 
338* >8 R >8 R 16 S >8 R 16 I 
345 <=2 S <=2 S <=8 S 2 S 16 I 
346* >8 R >8 R <=8 S >8 R >16 R 
351 4 S <=2 S <=8 S >8 R >16 R 
356 4 S <=2 S <=8 S >8 R 16 I 
359 <=2 S <=2 S <=8 S 2 S 16 I 
360* >8 R 8 I <=8 S >8 R >16 R 
363* >8 R >8 R <=8 S >8 R >16 R 
364 <=2 S <=2 S <=8 S >8 R 8 S 
365 4 S 4 S <=8 S >8 R 8 S 
366 <=2 S <=2 S <=8 S 4 I 8 S 
377 4 S <=2 S <=8 S >8 R 16 I 
378 >8 R >8 R <=8 S 8 R 8 S 
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380 4 S <=2 S <=8 S <=0.5 S 16 I 
381* >8 R >8 R <=8 S 8 R 16 I 
394 <=2 S <=2 S <=8 S <=0.5 S 16 I 
396 8 I <=2 S <=8 S 8 R 8 S 
397 >8 R >8 R <=8 S 1 S 16 I 
399 8 I 4 S 16 S >8 R >16 R 
404 4 S <=2 S <=8 S >8 R >16 R 
415 4 S 8 I <=8 S >8 R 8 S 
424 <=2 S <=2 S <=8 S >8 R 8 S 
427 <=2 S <=2 S <=8 S 2 S >16 R 
428 <=2 S <=2 S <=8 S <=0.5 S >16 R 
429 <=2 S <=2 S <=8 S >8 R 16 I 
430 >8 R >8 R <=8 S 4 I 16 I 
436* >8 R >8 R <=8 S 8 R 16 I 
437* >8 R 8 I <=8 S >8 R 16 I 
447 8 I <=2 S <=8 S 2 S 16 I 
448 >8 R 8 I >32 R >8 R >16 R 
450 <=2 S <=2 S <=8 S >8 R >16 R 
451 <=2 S <=2 S <=8 S >8 R 16 I 
455 >8 R >8 R <=8 S >8 R 16 I 
464 4 S <=2 S <=8 S 8 R >16 R 
471 >8 R >8 R <=8 S 4 I 16 I 
473 8 I <=2 S 16 S 2 S 16 I 
483 >8 R >8 R <=8 S 4 I >16 R 
487 8 I <=2 S <=8 S >8 R >16 R 
489* >8 R >8 R <=8 S 8 R >16 R 
490 <=2 S <=2 S <=8 S 2 S 16 I 
491 <=2 S <=2 S <=8 S 4 I 16 I 
494 <=2 S <=2 S <=8 S >8 R 8 S 
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Table A1 (continued) 
497* >8 R >8 R <=8 S >8 R >16 R 
498* >8 R >8 R 16 S >8 R >16 R 
499 <=2 S <=2 S <=8 S 2 S 16 I 
500 <=2 S <=2 S <=8 S 8 R 16 I 
504 <=2 S <=2 S <=8 S <=0.5 S 16 I 
505 8 I <=2 S 16 S >8 R 16 I 
509 <=2 S <=2 S <=8 S 8 R 8 S 
511 >8 R >8 R <=8 S >8 R 16 I 
518 <=2 S <=2 S <=8 S 1 S 16 I 
519 >8 R >8 R <=8 S 4 I 16 I 
520 4 S <=2 S <=8 S >8 R 16 I 
523 --- --- 32 R >256 R >32 R >256 R 
524 <=2 S <=2 S <=8 S >8 R 16 I 
525 4 S <=2 S <=8 S >8 R 16 I 
526 <=2 S <=2 S <=8 S >8 R 8 S 
527 4 S <=2 S <=8 S 4 I 16 I 
529 4 S <=2 S <=8 S 4 I 16 I 
530 <=2 S <=2 S <=8 S 2 S 16 I 
531 <=2 S <=2 S <=8 S >8 R 8 S 
532 <=2 S <=2 S <=8 S >8 R 8 S 
533 8 I <=2 S <=8 S 2 S 16 I 
535* >8 R >8 R <=8 S 8 R 16 I 
540 <=2 S <=2 S <=8 S >8 R 8 S 
543 <=2 S <=2 S <=8 S >8 R 8 S 
P. aeruginosa Collection 
1 <=2 S <=2 S <= 8 S <=1 S 8 S 
2 8 I <=2 S <= 8 S 2 S 16 I 
3 >8 R >8 R <= 8 S 4 I 16 I 
4 <=2 S <=2 S <= 8 S <=1 S 16 I 
  
88 
Table A1 (continued) 
5 8 I <=2 S <=8 S <=1 S 16 I 
6 <=2 S <=2 S <=8 S <=1 S 2 S 
7 >8 R >8 R <=8 S 8 R >16 R 
8 >8 R >8 R <=8 S 4 I 16 I 
9 <=2 S <=2 S <=8 S <=1 S 2 S 
11 <=2 S <=2 S <=8 S <=1 S 2 S 
12* >8 R >8 R >32 R >8 R >16 R 
13 <=2 S <=2 S <=8 S 4 I 2 S 
14 >8 R >8 R <=8 S 8 R 8 S 
15 <=2 S <=2 S <=8 S <=1 S 4 S 
16 >8 R >8 R <=8 S >8 R >16 R 
17* >8 R >8 R 16 S >8 R >16 R 
18 <=2 S <=2 S <=8 S <=1 S 8 S 
19 <=2 S <=2 S <=8 S <=1 S 2 S 
20 <=2 S <=2 S <=8 S <=1 S <=1 S 
21 >8 R >8 R <=8 S --- --- 4 S 
22 <=2 S <=2 S <=8 S <=1 S 2 S 
23 <=2 S <=2 S <=8 S <=1 S 2 S 
24* >8 R >8 R <=8 S 8 R 16 I 
25 <=2 S <=2 S <=8 S <=1 S <=1 S 
26 <=2 S <=2 S <=8 S <=1 S 2 S 
27 >8 R >8 R 32 I <=1 S 4 S 
28* >8 R >8 R <=8 S 8 R >16 R 
29* >8 R >8 R >32 R >8 R >16 R 
30 <=2 S <=2 S <=8 S <=1 S 2 S 
31 <=2 S <=2 S <=8 S <=1 S 2 S 
32 <=2 S <=2 S <=8 S 4 I 2 S 
33 <=2 S <=2 S <=8 S >8 R 16 I 
34 <=2 S <=2 S <=8 S >8 R >16 R 
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Table A1 (continued) 
35 <=2 S <=2 S <=8 S <=1 S 2 S 
36* >8 R >8 R <=8 S 8 R 16 I 
37 <=2 S <=2 S <=8 S 8 R 8 S 
38 --- --- 1 S 24 I 0.047 S 24 R 
39 1 S 0.38 S 0.5 S 0.047 S 0.125 S 
40 --- --- >256 R 24 I >32 R 12 I 
41 --- --- 1 S 16 S 1.5 S 24 R 
42 --- --- 0.75 S 8 S 0.125 S 1.5 S 
43 <=2 S <=2 S <=8 S <=1 S <=1 S 
44 >8 R >8 R <=8 S 8 R 8 S 
45 8 I <=2 S <=8 S 8 R 8 S 
46 <=2 S <=2 S <=8 S <=1 S 8 S 
47* >8 R >8 R <=8 S 8 R >16 R 
48 1 S 0.75 S 8 S 1.5 S 48 R 
49 <=2 S <=2 S <=8 S <=1 S 2 S 
50 <=2 S <=2 S <=8 S <=1 S 2 S 
51 4 S <=2 S <=8 S >8 R 16 I 
52 --- --- 3 S 32 I 0.19 S 12 I 
53 4 S <=2 S <=8 S 4 I 16 I 
54 <=2 S <=2 S <=8 S <=1 S 2 S 
55 <=2 S <=2 S <=8 S <=1 S 4 S 
56 <=2 S <=2 S <=8 S >8 R 4 S 
57 >8 R >8 R <=8 S 8 R 8 S 
58 8 I <=2 S <=8 S 8 R 8 S 
59 <=2 S <=2 S <=8 S <=1 S 2 S 
60 <=2 S <=2 S <=8 S <=1 S 2 S 
61* >8 R >8 R <=8 S 8 R 16 I 
62 <=2 S <=2 S <=8 S <=1 S 2 S 
63 <=2 S <=2 S <=8 S 4 I 8 S 
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Table A1 (continued) 
65 --- --- --- --- 1 S 6 I 48 R 
66* >8 R >8 R <=8 S >8 R 16 I 
67 >8 R >8 R <=8 S 8 R 8 S 
68 --- --- 4 S >256 R >32 R >256 R 
69 <=2 S <=2 S <=8 S <=1 S 2 S 
70 4 S <=2 S <=8 S <=1 S 4 S 
71 <=2 S <=2 S <=8 S <=1 S 8 S 
72 <=2 S <=2 S <=8 S <=1 S 4 S 
73 >8 R >8 R <=8 S 2 S >16 R 
74 >8 R >8 R <=8 S <=1 S 16 I 
75 >8 R >8 R <=8 S >8 R >16 R 
76 <=2 S <=2 S <=8 S <=1 S 8 S 
77 >8 R >8 R <=8 S >8 R 8 S 
78 <=2 S 4 S <=8 S 4 I 2 S 
79 <=2 S <=2 S <=8 S <=1 S 4 S 
80 <=2 S <=2 S <=8 S <=1 S 2 S 
81 1 S 4 S 1 S >32 R 48 R 
82 4 S <=2 S <=8 S <=1 S 8 S 
83* >8 R >8 R 16 S >8 R 16 I 
84* >8 R >8 R 16 S >8 R 16 I 
85* >8 R 8 I <=8 S >8 R >16 R 
86 <=2 S <=2 S <=8 S <=1 S 8 S 
87 >8 R 4 S 16 S 8 R >16 R 
88 <=2 S <=2 S <=8 S <=1 S 4 S 
89 >8 R >8 R 16 S 2 S 16 I 
90 4 S <=2 S <=8 S <=1 S 8 S 
91 <=2 S <=2 S <=8 S <=1 S 8 S 
92* >8 R >8 R >32 R >8 R >16 R 
93* >8 R >8 R <=8 S >8 R >16 R 
  
91 
Table A1 (continued) 
94 <=2 S <=2 S <=8 S 4 I 16 I 
95 <=2 S <=2 S <=8 S <=1 S 8 S 
96* >8 R >8 R <=8 S >8 R >16 R 
97 >8 R >8 R <=8 S 8 R 16 I 
98 <=2 S <=2 S <=8 S <=1 S 2 S 
99 <=2 S <=2 S <=8 S <=1 S 2 S 
100 >8 R >8 R <=8 S 8 R 8 S 
101 <=2 S <=2 S <=8 S <=1 S 16 I 
102 >8 R >8 R <=8 S 8 R 8 S 
103 <=2 S <=2 S <=8 S <=1 S 16 I 
104 <=2 S <=2 S <=8 S <=1 S 2 S 
105 <=2 S <=2 S <=8 S <=1 S 4 S 
106 <=2 S <=2 S <=8 S <=1 S 16 I 
107* >8 R >8 R <=8 S >8 R 16 I 
108 <=2 S <=2 S <=8 S <=1 S 4 S 
109 4 S <=2 S <=8 S 8 R 8 S 
110 <=2 S <=2 S <=8 S <=1 S 2 S 
111 >8 R >8 R <=8 S 8 R 8 S 
112 >8 R >8 R <=8 S 8 R 16 I 
113 <=2 S <=2 S <=8 S 2 S 4 S 
114 4 S <=2 S <=8 S <=1 S 8 S 
115* >8 R >8 R 16 S >8 R 16 I 
116 >8 R >8 R <=8 S <=1 S 16 I 
117 <=2 S <=2 S <=8 S <=1 S 8 S 
118 <=2 S <=2 S <=8 S 2 S 8 S 
119 <=2 S <=2 S <=8 S 8 R 16 I 
120 >8 R >8 R <=8 S 8 R 8 S 
121 4 S <=2 S <=8 S 8 R 8 S 
122 <=2 S <=2 S <=8 S <=1 S 4 S 
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Table A1 (continued) 
123 <=2 S <=2 S <=8 S >8 R >16 R 
124 4 S <=2 S <=8 S >8 R 16 I 
125 <=2 S <=2 S <=8 S 4 I 4 S 
126 <=2 S <=2 S <=8 S <=1 S 8 S 
127 <=2 S <=2 S <=8 S <=1 S 4 S 
128* >8 R >8 R 16 S 8 R 16 I 
129 8 I <=2 S 16 S >8 R 8 S 
130 <=2 S <=2 S <=8 S <=1 S 2 S 
131* >8 R >8 R 16 S >8 R >16 R 
132 <=2 S <=2 S <=8 S <=1 S 2 S 
133 >8 R >8 R <=8 S >8 R 16 I 
134 <=2 S <=2 S <=8 S >8 R 8 S 
135 <=2 S <=2 S <=8 S <=1 S 8 S 
136* >8 R >8 R <=8 S 4 S >16 R 
137 <=2 S <=2 S <=8 S 4 S >16 R 
138 <=2 S <=2 S <=8 S 4 S 4 S 
139 >8 R >8 R <=8 S 8 I 8 S 
140 <=2 S <=2 S <=8 S >8 R 8 S 
141 <=2 S <=2 S <=8 S <=1 S 4 S 
142 >8 R >8 R <=8 S 8 I 8 S 
143 <=2 S <=2 S <=8 S <=1 S 2 S 
144* >8 R >8 R <=8 S >8 R >16 R 
145 >8 R >8 R <=8 S 2 S >16 R 
146 <=2 S <=2 S <=8 S >8 R 16 I 
147 >8 R 4 S <=8 S >8 R 8 S 
148 4 S <=2 S <=8 S 8 I 8 S 
149 <=2 S <=2 S <=8 S <=1 S 2 S 
150 <=2 S <=2 S <=8 S <=1 S 2 S 
151* >8 R >8 R <=8 S >8 R >16 R 
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Table A2: Overall Susceptibility of All P. aeruginosa (n=287) Determined by BD Phoenix™ Automated Systems at the University of 
Kentucky HealthCare Clinical Microbiology Laboratory  
Antimicrobial Agent % Susceptible 
Gentamicin 54 
Tobramycin 62 
Amikacin 94 
Meropenem 38 
Ceftazidime 45 
Cefepime 39 
Aztreonam 24 
Piperacillin-Tazobactam 28 
Levofloxacin 25 
Ciprofloxacin 27 
Table A1 (continued) 
152 >8 R >8 R <=8 S 8 I 16 I 
153* >8 R >8 R <=8 S >8 R >16 R 
154 <=2 S <=2 S <=8 S <=1 S 2 S 
155 <=2 S <=2 S <=8 S <=1 S 4 S 
156 4 S <=2 S <=8 S 8 I 8 S 
157 <=2 S <=2 S <=8 S <=1 S 2 S 
158 4 S <=2 S <=8 S 8 I >16 R 
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Table A3: MIC (µg/ml) and Susceptibility Category of Each Antimicrobial Agent Against Each XDR-P. aeruginosa Isolate (n=49) 
Determined By BD Phoenix™ Automated Systems at the University of Kentucky HealthCare Clinical Microbiology Laboratory 
(S=susceptible; I=intermediate; R=resistant) 
Isolate Gentamicin Tobramycin Amikacin Levofloxacin Ciprofloxacin 
12 >8 R >8 R >32 R >4 R >2 R 
17 >8 R >8 R 16 S >4 R 2 I 
24 >8 R >8 R <=8 S >4 R >2 R 
28 >8 R >8 R <=8 S >4 R >2 R 
29 >8 R >8 R >32 R >4 R >2 R 
36 >8 R >8 R <=8 S >4 R >2 R 
47 >8 R >8 R <=8 S >4 R >2 R 
61 >8 R >8 R <=8 S >4 R >2 R 
66 >8 R >8 R <=8 S >4 R >2 R 
83 >8 R >8 R 16 S >4 R >2 R 
84 >8 R >8 R 16 S >4 R >2 R 
85 >8 R 8 I <=8 S >4 R >2 R 
88 >8 R >8 R <=8 S >4 R >2 R 
92 >8 R >8 R >32 R >4 R >2 R 
93 >8 R >8 R <=8 S >4 R >2 R 
96 >8 R >8 R <=8 S >4 R >2 R 
107 >8 R >8 R <=8 S >4 R >2 R 
115 >8 R >8 R 16 S >4 R >2 R 
128 >8 R >8 R 16 S >4 R >2 R 
131 >8 R >8 R 16 S >4 R >2 R 
136 >8 R >8 R <=8 S >4 R >2 R 
144 >8 R >8 R <=8 S >4 R >2 R 
151 >8 R >8 R <=8 S >4 R >2 R 
153 >8 R >8 R <=8 S >4 R >2 R 
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Table A3 (continued) 
157 >8 R >8 R <=8 S >4 R >2 R 
184 >8 R >8 R <=8 S >4 R >2 R 
208 >8 R >8 R <=8 S >4 R >2 R 
211 >8 R 8 I <=8 S >4 R >2 R 
234 >8 R >8 R <=8 S >4 R >2 R 
251 >8 R >8 R <=8 S >4 R >2 R 
259 >8 R >8 R <=8 S >4 R >2 R 
279 >8 R >8 R <=8 S >4 R >2 R 
297 >8 R >8 R <=8 S >4 R >2 R 
300 >8 R >8 R <=8 S >4 R >2 R 
313 >8 R >8 R <=8 S >4 R >2 R 
326 >8 R >8 R <=8 S >4 R >2 R 
327 >8 R >8 R <=8 S >4 R >2 R 
337 >8 R >8 R <=8 S >4 R >2 R 
338 >8 R >8 R 16 S >4 R >2 R 
346 >8 R >8 R <=8 S >4 R >2 R 
360 >8 R 8 I <=8 S >4 R >2 R 
363 >8 R >8 R <=8 S >4 R >2 R 
381 >8 R >8 R <=8 S >4 R >2 R 
436 >8 R >8 R <=8 S >4 R >2 R 
437 >8 R 8 I <=8 S >4 R >2 R 
489 >8 R >8 R <=8 S >4 R >2 R 
497 >8 R >8 R <=8 S >4 R >2 R 
498 >8 R >8 R 16 S >4 R >2 R 
535 >8 R >8 R <=8 S >4 R >2 R 
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Table A3 (continued) 
Isolate Cefepime Ceftazidime Aztreonam Meropenem Piperacillin-
Tazobactam 
12 >16 R 16 I >16 R >8 R 64/4 I 
17 >16 R >16 R >16 R >8 R >64/4 R 
24 16 I >16 R 16 I 8 R 64/4 I 
28 >16 R >16 R >16 R 8 R >64/4 R 
29 >16 R 16 I >16 R >8 R 64/4 I 
36 16 I >16 R 16 I 8 R 64/4 I 
47 >16 R >16 R >16 R 8 R >64/4 R 
61 16 I 16 I 16 I 8 R 64/4 I 
66 16 I >16 R >16 R >8 R 32/4 I 
83 16 I >16 R 16 I >8 R >64/4 R 
84 16 I 16 I 16 I >8 R 64/4 I 
85 >16 R >16 R >16 R >8 R >64/4 R 
88 >16 R >16 R 16 I >8 R >64/4 R 
92 >16 R >16 R >16 R >8 R >64/4 R 
93 >16 R >16 R >16 R >8 R >64/4 R 
96 >16 R 16 I >16 R >8 R >64/4 R 
107 16 I 16 I >16 R >8 R >64/4 R 
115 16 I 16 I 16 I >8 R >64/4 R 
128 16 I 16 I 16 I 8 R 32/4 I 
131 >16 R >16 R >16 R >8 R 64/4 I 
136 >16 R >16 R >16 R 4 I >64/4 R 
144 >16 R >16 R >16 R >8 R >64/4 R 
151 >16 R 16 I >16 R >8 R >64/4 R 
153 >16 R 16 I >16 R >8 R >64/4 R 
  
97 
Table A3 (continued) 
157 >16 R >16 R >16 R >8 R 64/4 I 
184 16 I >16 R >16 R >8 R >64/4 R 
208 16 I 16 I 16 I >8 R >64/4 R 
211 16 I >16 R 16 I 8 R >64/4 R 
234 16 I >16 R 16 I >8 R >64/4 R 
251 16 I 16 I 16 I 8 R 64/4 I 
259 >16 R >16 R >16 R >8 R >64/4 R 
279 16 I 16 I >16 R >8 R >64/4 R 
297 >16 R 16 I >16 R >8 R >64/4 R 
300 >16 R 16 I >16 R >8 R >64/4 R 
313 >16 R 16 I >16 R >8 R >64/4 R 
326 >16 R >16 R >16 R >8 R >64/4 R 
327 16 I 16 I 16 I 8 R 64/4 I 
337 16 I >16 R >16 R >8 R 64/4 I 
338 16 I >16 R 16 I >8 R >64/4 R 
346 >16 R >16 R >16 R >8 R 64/4 I 
360 >16 R >16 R >16 R >8 R >64/4 R 
363 >16 R >16 R >16 R >8 R 32/4 I 
381 16 I >16 R >16 R 8 R >64/4 R 
436 16 I >16 R 16 I 8 R >64/4 R 
437 16 I >16 R >16 R >8 R >64/4 R 
489 >16 R >16 R >16 R 8 R >64/4 R 
497 >16 R >16 R >16 R >8 R 64/4 I 
498 >16 R >16 R >16 R >8 R >64/4 R 
535 16 I 16 I 16 I 8 R >64/4 R 
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Table A4: MIC (µg/ml) and Susceptibility Category of Each Antimicrobial Agent Against Each XDR-P. aeruginosa Isolate (n=49) 
Determined By Broth Microdilution at the University of Kentucky Pharmacy Practice and Science Core Lab (S=susceptible; 
I=intermediate; R=resistant) 
Isolate Gentamicin Tobramycin Amikacin Piperacillin-
Tazobactam 
Levofloxacin Imipenem 
12 >256 R >128 R 16 S 256/4 R 64 R 16 R 
17 256 R 128 R 16 S 512/4 R 16 R 32 R 
24 >256 R >128 R 16 S 512/4 R 64 R 16 R 
28 >256 R >128 R 32 I >512/4 R 8 R 16 R 
29 32 R >128 R 128 R 64/4 I 64 R 4 I 
36 >256 R 128 R 16 S 256/4 R 32 R 16 R 
47 256 R 128 R 16 S 512/4 R 32 R 32 R 
61 128 R 128 R 16 S 128/4 R 64 R 32 R 
66 128 R 64 R 8 S 32/4 I 64 R 16 R 
83 >256 R 128 R 16 S 512/4 R 64 R 32 R 
84 >256 R >128 R 16 S 128/4 R 32 R 32 R 
85 128 R 32 R 8 S >512/4 R 64 R 32 R 
88 256 R 128 R 32 I 512/4 R 32 R >128 R 
92 64 R >128 R 512 R 512/4 R 64 R 16 R 
93 256 R 128 R 16 S 512/4 R 64 R 64 R 
96 >256 R >128 R 8 S >512/4 R 128 R 8 R 
107 >256 R >128 R 16 S 256/4 R 64 R 8 R 
115 >256 R >128 R 16 S 64/4 I 16 R 32 R 
128 256 R 128 R 16 S 32/4 I 64 R 32 R 
131 >256 R 128 R 16 S 128/4 R 32 R 32 R 
136 >256 R 128 R 16 S 256/4 R 64 R 4 I 
144 >256 R >128 R 16 S 512/4 R 128 R 16 R 
151 >256 R >128 R 16 S 512/4 R 128 R 8 R 
  
99 
Table A4 (continued) 
153 >256 R >128 R 8 S 256/4 R 128 R 16 R 
157 128 R 64 R 8 S 64/4 I 128 R 32 R 
184 >256 R >128 R 8 S 512/4 R 128 R 16 R 
208 >256 R >128 R 16 S 64/4 I 32 R 32 R 
211 16 R 16 R <=0.5 S 256/4 R 32 R 16 R 
234 >256 R >128 R 16 S 128/4 R 32 R 32 R 
251 >256 R >128 R 16 S 512/4 R 64 R 8 R 
259 >256 R >128 R 8 S 256/4 R 64 R 16 R 
279 >256 R >128 R 16 S 256/4 R 128 R 16 R 
297 >256 R >128 R 8 S 512/4 R 128 R 16 R 
300 >256 R >128 R 16 S 512/4 R 128 R 8 R 
313 >256 R >128 R 8 S 256/4 R 128 R 16 R 
326 >256 R >128 R 16 S 512/4 R 128 R 8 R 
327 >256 R >128 R 16 S 32/4 I 32 R 32 R 
337 >256 R 64 R 32 I 256/4 R 128 R 32 R 
338 >256 R 64 R 8 S 256/4 R 64 R 16 R 
346 >256 R >128 R >512 R >512/4 R 128 R 16 R 
360 128 R 32 R 8 S >512/4 R 64 R 32 R 
363 >256 R >128 R 16 S 128/4 R 128 R 16 R 
381 >256 R >128 R 16 S 512/4 R 32 R 32 R 
436 >256 R >128 R 16 S 256/4 R 64 R 8 R 
437 256 R 32 R 8 S 512/4 R 32 R 32 R 
489 >256 R >128 R 16 S 512/4 R 32 R 16 R 
497 >256 R >128 R 32 I 256/4 R 256 R 32 R 
498 >256 R >128 R 32 I >512/4 R 128 R 32 R 
535 >256 R >128 R 16 S 512/4 R 64 R 8 R 
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Table A4 (continued) 
Isolate Meropenem Cefepime Aztreonam Aztreonam-
Avibactam 
Ceftazidime Ceftazidime-
Avibactam 
12 16 R 32 R 16 I 8/4 S 32 R 2/4 S 
17 64 R 128 R 128 R 32/4 R 128 R 8/4 S 
24 16 R 32 R 16 I 8/4 S 32 R 2/4 S 
28 16 R 32 R 64 R 16/4 I 128 R 8/4 S 
29 16 R 32 R 32 R 16/4 I 16 I 2/4 S 
36 16 R 16 I 16 I 8/4 S 32 R 2/4 S 
47 16 R 32 R 128 R 8/4 S 64 R 8/4 S 
61 16 R 16 I 8 S 4/4 S 16 I 2/4 S 
66 32 R 32 R 64 R 32/4 R 8 S 8/4 S 
83 16 R 32 R 16 I 4/4 S 64 R 2/4 S 
84 32 R 16 I 8 S 8/4 S 16 I 2/4 S 
85 32 R 32 R 128 R 16/4 I 128 R 16/4 R 
88 >128 R 128 R 64 R 8/4 S 256 R 256/4 R 
92 32 R 32 R 32 R 16/4 I 32 R 8/4 S 
93 32 R 32 R 128 R 8/4 S 128 R 8/4 S 
96 32 R 32 R 64 R 64/4 R 32 R 8/4 S 
107 32 R 32 R 128 R 64/4 R 32 R 8/4 S 
115 16 R 16 I 8 S 4/4 S 16 I 2/4 S 
128 16 R 16 I 4 S 4/4 S 4 S 1/4 S 
131 64 R 64 R 32 R 16/4 I 32 R 4/4 S 
136 8 R 32 R 64 R 32/4 R 32 R 2/4 S 
144 32 R 32 R 128 R 64/4 R 64 R 8/4 S 
151 32 R 32 R 128 R 64/4 R 32 R 4/4 S 
153 32 R 32 R 64 R 64/4 R 32 R 8/4 S 
157 64 R 128 R 128 R 128/4 R 16 I 16/4 R 
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Table A4 (continued) 
184 32 R 32 R 64 R 64/4 R 256 R 256/4 R 
208 32 R 32 R 16 I 8/4 S 8 S 2/4 S 
211 16 R 16 I 32 R 8/4 S 16 I 2/4 S 
234 32 R 16 I 16 I 8/4 S 16 I 2/4 S 
251 16 R 32 R 32 R 8/4 S 32 R 2/4 S 
259 32 R >256 R 32 R 256/4 R 64 R 4/4 S 
279 32 R >256 R 128 R 64/4 R 32 R 8/4 S 
297 32 R 32 R 64 R 64/4 R 32 R 8/4 S 
300 32 R 32 R 64 R 64/4 R 32 R 8/4 S 
313 64 R 32 R 64 R 64/4 R 32 R 4/4 S 
326 32 R 32 R 64 R 32/4 R 32 R 4/4 S 
327 16 R 16 I 32 R 16/4 I 16 I 2/4 S 
337 32 R 32 R 32 R 8/4 S 64 R 4/4 S 
338 8 R --- --- 64 R 8/4 S 32 R 4/4 S 
346 32 R >256 R >512 R 32/4 R >256 R 4/4 S 
360 32 R 32 R 128 R 8/4 S 128 R 8/4 S 
363 32 R 64 R >512 R 32/4 R 64 R 4/4 S 
381 16 R 16 I 64 R 16/4 I 64 R 4/4 S 
436 8 R 32 R 16 I 8/4 S 16 I 1/4 S 
437 32 R 16 I 32 R 16/4 I 64 R 8/4 S 
489 16 R 32 R 32 R 8/4 S 32 R 4/4 S 
497 128 R 32 R 64 R 32/4 R 32 R 8/4 S 
498 128 R 64 R 128 R 64/4 R 128 R 32/4 R 
535 16 R 32 R 16 I 16/4 I 32 R 2/4 S 
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Table A4 (continued) 
Isolate Ceftolozane-Tazobactam Polymyxin B Colistin 
12 1/4 S 0.5 S 1 S 
17 2/4 S 0.25 S 0.5 S 
24 1/4 S 0.5 S 1 S 
28 2/4 S 0.25 S 0.5 S 
29 1/4 S 0.25 S 0.5 S 
36 1/4 S 0.25 S 1 S 
47 2/4 S 0.25 S 0.5 S 
61 1/4 S 0.25 S 1 S 
66 0.5/4 S 0.25 S 0.5 S 
83 1/4 S 0.25 S 0.5 S 
84 1/4 S 0.5 S 1 S 
85 4/4 S 0.5 S 0.5 S 
88 128/4 R 0.25 S 0.5 S 
92 1/4 S 0.5 S 1 S 
93 4/4 S 0.5 S 0.5 S 
96 1/4 S 0.5 S 1 S 
107 1/4 S 1 S 1 S 
115 1/4 S 1 S 1 S 
128 1/4 S 0.5 S 1 S 
131 1/4 S 1 S 1 S 
136 0.5/4 S 0.5 S 1 S 
144 1/4 S 0.5 S 0.5 S 
151 1/4 S 0.5 S 1 S 
153 0.5/4 S 0.5 S 1 S 
157 2/4 S 0.5 S 1 S 
184 2/4 S 0.5 S 0.5 S 
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Table A4 (continued) 
208 1/4 S 0.5 S 0.5 S 
211 0.5/4 S 0.5 S 1 S 
234 1/4 S 0.5 S 1 S 
251 1/4 S 0.25 S 1 S 
259 1/4 S 1 S 1 S 
279 2/4 S 0.5 S 2 S 
297 1/4 S 0.5 S 1 S 
300 1/4 S 0.5 S 1 S 
313 1/4 S 0.5 S 1 S 
326 1/4 S 0.5 S 1 S 
327 2/4 S 0.5 S 1 S 
337 2/4 S 0.5 S 1 S 
338 1/4 S 0.5 S <=0.125 S 
346 32/4 R 0.5 S 1 S 
360 4/4 S 0.5 S 1 S 
363 32/4 R 0.5 S 1 S 
381 2/4 S 0.5 S 0.5 S 
436 1/4 S 0.5 S 1 S 
437 0.5/4 S 0.5 S 1 S 
489 1/4 S 0.5 S 1 S 
497 2/4 S 1 S 1 S 
498 4/4 S 1 S 0.5 S 
535 1/4 S 0.5 S 1 S 
 
 
 
  
104 
Table A5: Comparison of MIC and Categorical Susceptibility of Each Antimicrobial Agent Determined by Broth Microdilution at the 
University of Kentucky Pharmacy Practice and Science Core Lab and BD Phoenix™ Automated Systems at the University of 
Kentucky HealthCare Clinical Microbiology Laboratory for Each XDR-P. aeruginosa Isolate (n=49) (BMD=broth microdilution; 
P=BD Phoenix™; EA=essential agreement; CA=categorical agreement; U=unknown; Y=yes; N=no or none; ME=minor error; 
MAE=major error; VME=very major error; GEN=gentamicin, TOB=tobramycin, AMK=amikacin; MEM=meropenem; 
PTC=piperacillin-tazobactam; CFP=cefepime; CAZ=ceftazidime; LEV=levofloxacin; AZT=aztreonam) 
Isolate GEN 
BMD 
GEN 
BMD 
GEN 
P 
GEN 
P EA CA Error 
TOB 
BMD 
TOB 
BMD 
TOB 
P 
TOB 
P EA CA Error 
12 >256 R >8 R U Y N >128 R >8 R U Y N 
17 256 R >8 R U Y N 128 R >8 R U Y N 
24 >256 R >8 R U Y N >128 R >8 R U Y N 
28 >256 R >8 R U Y N >128 R >8 R U Y N 
29 32 R >8 R U Y N >128 R >8 R U Y N 
36 >256 R >8 R U Y N 128 R >8 R U Y N 
47 256 R >8 R U Y N 128 R >8 R U Y N 
61 128 R >8 R U Y N 128 R >8 R U Y N 
66 128 R >8 R U Y N 64 R >8 R U Y N 
83 >256 R >8 R U Y N 128 R >8 R U Y N 
84 >256 R >8 R U Y N >128 R >8 R U Y N 
85 128 R >8 R U Y N 32 R 8 I N N ME 
88 256 R >8 R U Y N 128 R >8 R U Y N 
92 64 R >8 R U Y N >128 R >8 R U Y N 
93 256 R >8 R U Y N 128 R >8 R U Y N 
96 >256 R >8 R U Y N >128 R >8 R U Y N 
107 >256 R >8 R U Y N >128 R >8 R U Y N 
115 >256 R >8 R U Y N >128 R >8 R U Y N 
128 256 R >8 R U Y N 128 R >8 R U Y N 
131 >256 R >8 R U Y N 128 R >8 R U Y N 
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Table A5 (continued) 
136 >256 R >8 R U Y N 128 R >8 R U Y N 
144 >256 R >8 R U Y N >128 R >8 R U Y N 
151 >256 R >8 R U Y N >128 R >8 R U Y N 
153 >256 R >8 R U Y N >128 R >8 R U Y N 
157 128 R >8 R U Y N 64 R >8 R U Y N 
184 >256 R >8 R U Y N >128 R >8 R U Y N 
208 >256 R >8 R U Y N >128 R >8 R U Y N 
211 16 R >8 R U Y N 16 R 8 I Y N ME 
234 >256 R >8 R U Y N >128 R >8 R U Y N 
251 >256 R >8 R U Y N >128 R >8 R U Y N 
259 >256 R >8 R U Y N >128 R >8 R U Y N 
279 >256 R >8 R U Y N >128 R >8 R U Y N 
297 >256 R >8 R U Y N >128 R >8 R U Y N 
300 >256 R >8 R U Y N >128 R >8 R U Y N 
313 >256 R >8 R U Y N >128 R >8 R U Y N 
326 >256 R >8 R U Y N >128 R >8 R U Y N 
327 >256 R >8 R U Y N >128 R >8 R U Y N 
337 >256 R >8 R U Y N 64 R >8 R U Y N 
338 >256 R >8 R U Y N 64 R >8 R U Y N 
346 >256 R >8 R U Y N >128 R >8 R U Y N 
360 128 R >8 R U Y N 32 R 8 I N N ME 
363 >256 R >8 R U Y N >128 R >8 R U Y N 
381 >256 R >8 R U Y N >128 R >8 R U Y N 
436 >256 R >8 R U Y N >128 R >8 R U Y N 
437 256 R >8 R U Y N 32 R 8 I N N ME 
489 >256 R >8 R U Y N >128 R >8 R U Y N 
497 >256 R >8 R U Y N >128 R >8 R U Y N 
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Table A5 (continued) 
498 >256 R >8 R U Y N >128 R >8 R U Y N 
535 >256 R >8 R U Y N >128 R >8 R U Y N 
               
Isolate AMK 
BMD 
AMK 
BMD 
AMK 
P 
AMK 
P EA CA Error 
MEM 
BMD 
MEM 
BMD 
MEM 
P 
MEM 
P EA CA Error 
12 16 S >32 R N N MAE 16 R >8 R U Y N 
17 16 S 16 S Y Y N 64 R >8 R U Y N 
24 16 S <=8 S U Y N 16 R 8 R Y Y N 
28 32 I <=8 S N N ME 16 R 8 R Y Y N 
29 128 R >32 R U Y N 16 R >8 R U Y N 
36 16 S <=8 S U Y N 16 R 8 R Y Y N 
47 16 S <=8 S U Y N 16 R 8 R Y Y N 
61 16 S <=8 S U Y N 16 R 8 R Y Y N 
66 8 S <=8 S U Y N 32 R >8 R U Y N 
83 16 S 16 S Y Y N 16 R >8 R U Y N 
84 16 S 16 S Y Y N 32 R >8 R U Y N 
85 8 S <=8 S U Y N 32 R >8 R U Y N 
88 32 I <=8 S N N ME >128 R >8 R U Y N 
92 512 R >32 R U Y N 32 R >8 R U Y N 
93 16 S <=8 S U Y N 32 R >8 R U Y N 
96 8 S <=8 S U Y N 32 R >8 R U Y N 
107 16 S <=8 S U Y N 32 R >8 R U Y N 
115 16 S 16 S Y Y N 16 R >8 R U Y N 
128 16 S 16 S Y Y N 16 R 8 R Y Y N 
131 16 S 16 S Y Y N 64 R >8 R U Y N 
136 16 S <=8 S U Y N 8 R 4 I Y N ME 
144 16 S <=8 S U Y N 32 R >8 R U Y N 
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Table A5 (continued) 
151 16 S <=8 S U Y N 32 R >8 R U Y N 
153 8 S <=8 S U Y N 32 R >8 R U Y N 
157 8 S <=8 S U Y N 64 R >8 R U Y N 
184 8 S <=8 S U Y N 32 R >8 R U Y N 
208 16 S <=8 S U Y N 32 R >8 R U Y N 
211 <=0.5 S <=8 S U Y N 16 R 8 R Y Y N 
234 16 S <=8 S U Y N 32 R >8 R U Y N 
251 16 S <=8 S U Y N 16 R 8 R Y Y N 
259 8 S <=8 S U Y N 32 R >8 R U Y N 
279 16 S <=8 S U Y N 32 R >8 R U Y N 
297 8 S <=8 S U Y N 32 R >8 R U Y N 
300 16 S <=8 S U Y N 32 R >8 R U Y N 
313 8 S <=8 S U Y N 64 R >8 R U Y N 
326 16 S <=8 S U Y N 32 R >8 R U Y N 
327 16 S <=8 S U Y N 16 R 8 R Y Y N 
337 32 I <=8 S N N ME 32 R >8 R U Y N 
338 8 S 16 S Y Y N 8 R >8 R U Y N 
346 >512 R <=8 S N N VME 32 R >8 R U Y N 
360 8 S <=8 S U Y N 32 R >8 R U Y N 
363 16 S <=8 S U Y N 32 R >8 R U Y N 
381 16 S <=8 S U Y N 16 R 8 R Y Y N 
436 16 S <=8 S U Y N 8 R 8 R Y Y N 
437 8 S <=8 S U Y N 32 R >8 R U Y N 
489 16 S <=8 S U Y N 16 R 8 R Y Y N 
497 32 I <=8 S N N ME 128 R >8 R U Y N 
498 32 I 16 S N N ME 128 R >8 R U Y N 
535 16 S <=8 S U Y N 16 R 8 R Y Y N 
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Table A5 (continued)  
Isolate PTC 
BMD 
PTC 
BMD 
PTC 
P 
PTC 
P EA CA Error 
CFP 
BMD 
CFP 
BMD 
CFP 
P 
CFP 
P EA CA Error 
12 256 R 64/4 I N N ME 32 R >16 R U Y N 
17 512 R >64/4 R U Y N 128 R >16 R U Y N 
24 512 R 64/4 I N N ME 32 R 16 I Y N ME 
28 >512 R >64/4 R U Y N 32 R >16 R U Y N 
29 64 I 64/4 I Y Y N 32 R >16 R U Y N 
36 256 R 64/4 I N N ME 16 I 16 I Y Y N 
47 512 R >64/4 R U Y N 32 R >16 R U Y N 
61 128 R 64/4 I Y N ME 16 I 16 I Y Y N 
66 32 I 32/4 I Y Y N 32 R 16 I Y N ME 
83 512 R >64/4 R U Y N 32 R 16 I Y N ME 
84 128 R 64/4 I Y N ME 16 I 16 I Y Y N 
85 >512 R >64/4 R U Y N 32 R >16 R U Y N 
88 512 R >64/4 R U Y N 128 R >16 R U Y N 
92 512 R >64/4 R U Y N 32 R >16 R U Y N 
93 512 R >64/4 R U Y N 32 R >16 R U Y N 
96 >512 R >64/4 R U Y N 32 R >16 R U Y N 
107 256 R >64/4 R U Y N 32 R 16 I Y N ME 
115 64 I >64/4 R U N ME 16 I 16 I Y Y N 
128 32 I 32/4 I Y Y N 16 I 16 I Y Y N 
131 128 R 64/4 I Y N ME 64 R >16 R U Y N 
136 256 R >64/4 R U Y N 32 R >16 R U Y N 
144 512 R >64/4 R U Y N 32 R >16 R U Y N 
151 512 R >64/4 R U Y N 32 R >16 R U Y N 
153 256 R >64/4 R U Y N 32 R >16 R U Y N 
157 64 I 64/4 I Y Y N 128 R >16 R U Y N 
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Table A5 (continued) 
184 512 R >64/4 R U Y N 32 R 16 I Y N ME 
208 64 I >64/4 R U N ME 32 R 16 I Y N ME 
211 256 R >64/4 R U Y N 16 I 16 I Y Y N 
234 128 R >64/4 R U Y N 16 I 16 I Y Y N 
251 512 R 64/4 I N N ME 32 R 16 I Y N ME 
259 256 R >64/4 R U Y N >256 R >16 R U Y N 
279 256 R >64/4 R U Y N >256 R 16 I N N ME 
297 512 R >64/4 R U Y N 32 R >16 R U Y N 
300 512 R >64/4 R U Y N 32 R >16 R U Y N 
313 256 R >64/4 R U Y N 32 R >16 R U Y N 
326 512 R >64/4 R U Y N 32 R >16 R U Y N 
327 32 I 64/4 I Y Y N 16 I 16 I Y Y N 
337 256 R 64/4 I N N ME 32 R 16 I Y N ME 
338 256 R >64/4 R U Y N --  --  16 I U U U 
346 >512 R 64/4 I U N ME >256 R >16 R U Y N 
360 >512 R >64/4 R U Y N 32 R >16 R U Y N 
363 128 R 32/4 I N N ME 64 R >16 R U Y N 
381 512 R >64/4 R U Y N 16 I 16 I Y Y N 
436 256 R >64/4 R U Y N 32 R 16 I Y N ME 
437 512 R >64/4 R U Y N 16 I 16 I Y Y N 
489 512 R >64/4 R U Y N 32 R >16 R U Y N 
497 256 R 64/4 I N N ME 32 R >16 R U Y N 
498 >512 R >64/4 R U Y N 64 R >16 R U Y N 
535 512 R >64/4 R U Y N 32 R 16 I Y N ME 
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Table A5 (continued) 
Isolate CAZ 
BMD 
CAZ 
BMD 
CAZ 
P 
CAZ 
P EA CA Error 
LEV 
BMD 
LEV 
BMD 
LEV 
P 
LEV 
P EA CA Error 
12 32 R 16 I Y N ME 64 R >4 R U Y N 
17 128 R >16 R U Y N 16 R >4 R U Y N 
24 32 R >16 R U Y N 64 R >4 R U Y N 
28 128 R >16 R U Y N 8 R >4 R U Y N 
29 16 I 16 I Y Y N 64 R >4 R U Y N 
36 32 R >16 R U Y N 32 R >4 R U Y N 
47 64 R >16 R U Y N 32 R >4 R U Y N 
61 16 I 16 I Y Y N 64 R >4 R U Y N 
66 8 S >16 R N N MAE 64 R >4 R U Y N 
83 64 R >16 R U Y N 64 R >4 R U Y N 
84 16 I 16 I Y Y N 32 R >4 R U Y N 
85 128 R >16 R U Y N 64 R >4 R U Y N 
88 256 R >16 R U Y N 32 R >4 R U Y N 
92 32 R >16 R U Y N 64 R >4 R U Y N 
93 128 R >16 R U Y N 64 R >4 R U Y N 
96 32 R 16 I Y N ME 128 R >4 R U Y N 
107 32 R 16 I Y N ME 64 R >4 R U Y N 
115 16 I 16 I Y Y N 16 R >4 R U Y N 
128 4 S 16 I N N ME 64 R >4 R U Y N 
131 32 R >16 R U Y N 32 R >4 R U Y N 
136 32 R >16 R U Y N 64 R >4 R U Y N 
144 64 R >16 R U Y N 128 R >4 R U Y N 
151 32 R 16 I Y N ME 128 R >4 R U Y N 
153 32 R 16 I Y N ME 128 R >4 R U Y N 
157 16 I >16 R U N ME 128 R >4 R U Y N 
  
111 
Table A5 (continued) 
184 256 R >16 R U Y N 128 R >4 R U Y N 
208 8 S 16 I Y N ME 32 R >4 R U Y N 
211 16 I >16 R U N ME 32 R >4 R U Y N 
234 16 I >16 R U N ME 32 R >4 R U Y N 
251 32 R 16 I Y N ME 64 R >4 R U Y N 
259 64 R >16 R U Y N 64 R >4 R U Y N 
279 32 R 16 I Y N ME 128 R >4 R U Y N 
297 32 R 16 I Y N ME 128 R >4 R U Y N 
300 32 R 16 I Y N ME 128 R >4 R U Y N 
313 32 R 16 I Y N ME 128 R >4 R U Y N 
326 32 R >16 R U Y N 128 R >4 R U Y N 
327 16 I 16 I Y Y N 32 R >4 R U Y N 
337 64 R >16 R U Y N 128 R >4 R U Y N 
338 32 R >16 R U Y N 64 R >4 R U Y N 
346 >256 R >16 R U Y N 128 R >4 R U Y N 
360 128 R >16 R U Y N 64 R >4 R U Y N 
363 64 R >16 R U Y N 128 R >4 R U Y N 
381 64 R >16 R U Y N 32 R >4 R U Y N 
436 16 I >16 R U N ME 64 R >4 R U Y N 
437 64 R >16 R U Y N 32 R >4 R U Y N 
489 32 R >16 R U Y N 32 R >4 R U Y N 
497 32 R >16 R U Y N 256 R >4 R U Y N 
498 128 R >16 R U Y N 128 R >4 R U Y N 
535 32 R 16 I Y N ME 64 R >4 R U Y N 
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Table A5 (continued) 
Isolate AZT 
BMD 
AZT 
BMD AZT P AZT P EA CA  Error 
12 16 I >16 R U N ME 
17 128 R >16 R U Y N 
24 16 I 16 I Y Y N 
28 64 R >16 R U Y N 
29 32 R >16 R U Y N 
36 16 I 16 I Y Y N 
47 128 R >16 R U Y N 
61 8 S 16 I Y N ME 
66 64 R >16 R U Y N 
83 16 I 16 I Y Y N 
84 8 S 16 I Y N ME 
85 128 R >16 R U Y N 
88 64 R 16 I N N ME 
92 32 R >16 R U Y N 
93 128 R >16 R U Y N 
96 64 R >16 R U Y N 
107 128 R >16 R U Y N 
115 8 S 16 I Y N ME 
128 4 S 16 I N N ME 
131 32 R >16 R U Y N 
136 64 R >16 R U Y N 
144 128 R >16 R U Y N 
151 128 R >16 R U Y N 
153 64 R >16 R U Y N 
157 128 R >16 R U Y N 
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Table A5 (continued) 
184 64 R >16 R U Y N 
208 16 I 16 I Y Y N 
211 32 R 16 I Y N ME 
234 16 I 16 I Y Y N 
251 32 R 16 I Y N ME 
259 32 R >16 R U Y N 
279 128 R >16 R U Y N 
297 64 R >16 R U Y N 
300 64 R >16 R U Y N 
313 64 R >16 R U Y N 
326 64 R >16 R U Y N 
327 32 R 16 I Y N ME 
337 32 R >16 R U Y N 
338 64 R 16 I N N ME 
346 >512 R >16 R U Y N 
360 128 R >16 R U Y N 
363 >512 R >16 R U Y N 
381 64 R >16 R U Y N 
436 16 I 16 I Y Y N 
437 32 R >16 R U Y N 
489 32 R >16 R U Y N 
497 64 R >16 R U Y N 
498 128 R >16 R U Y N 
535 16 I 16 I Y Y N 
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Table A6: Fold Decrease in MIC Between New and Old Beta-Lactam/Beta-Lactamase Inhibitors Against Each XDR-P. aeruginosa 
Isolate (n=49)(PTC=piperacillin-tazobactam; C/T=ceftolozane-tazobactam; CAZ=ceftazidime; CZA=ceftazidime-avibactam; 
AZT=aztreonam; AZT-AVI=aztreonam-avibactam 
Isolate PTC 
MIC 
(µg/ml) 
C/T MIC 
(µg/ml) 
MIC 
Change 
From PTC 
To C/T 
CAZ MIC 
(µg/ml) 
CZA MIC 
(µg/ml) 
MIC 
Change 
From CAZ 
to CZA 
AZT MIC 
(µg/ml) 
AZT-AVI 
MIC 
(µg/ml) 
MIC 
Change 
From 
AZT TO 
AZT-AVI 
12 256/4 1/4 256 32 2/4 16 16 8/4 2 
17 512/4 2/4 256 128 8/4 16 128 32/4 4 
24 512/4 1/4 512 32 2/4 16 16 8/4 2 
28 >512/4 2/4 >256 128 8/4 16 64 16/4 4 
29 64/4 1/4 64 16 2/4 8 32 16/4 2 
36 256/4 1/4 256 32 2/4 16 16 8/4 2 
47 512/4 2/4 256 64 8/4 8 128 8/4 16 
61 128/4 1/4 128 16 2/4 8 8 4/4 2 
66 32/4 0.5/4 64 8 8/4 1 64 32/4 2 
83 512/4 1/4 512 64 2/4 32 16 4/4 4 
84 128/4 1/4 128 16 2/4 8 8 8/4 1 
85 >512/4 4/4 >128 128 16/4 8 128 16/4 8 
88 512/4 128/4 4 256 256/4 1 64 8/4 8 
92 512/4 1/4 512 32 8/4 4 32 16/4 2 
93 512/4 4/4 128 128 8/4 16 128 8/4 16 
96 >512/4 1/4 >512 32 8/4 4 64 64/4 1 
107 256/4 1/4 256 32 8/4 4 128 64/4 2 
115 64/4 1/4 64 16 2/4 8 8 4/4 2 
128 32/4 1/4 32 4 1/4 4 4 4/4 1 
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Table A6 (continued) 
131 128/4 1/4 128 32 4/4 8 32 16/4 2 
136 256/4 0.5/4 512 32 2/4 16 64 32/4 2 
144 512/4 1/4 512 64 8/4 8 128 64/4 2 
151 512/4 1/4 512 32 4/4 8 128 64/4 2 
153 256/4 0.5/4 512 32 8/4 4 64 64/4 1 
157 64/4 2/4 32 16 16/4 1 128 128/4 1 
184 512/4 2/4 256 256 256/4 1 64 64/4 1 
208 64/4 1/4 64 8 2/4 4 16 8/4 2 
211 256/4 0.5/4 512 16 2/4 8 32 8/4 4 
234 128/4 1/4 128 16 2/4 8 16 8/4 2 
251 512/4 1/4 512 32 2/4 16 32 8/4 4 
259 256/4 1/4 256 64 4/4 16 32 256/4 0.125 
279 256/4 2/4 128 32 8/4 4 128 64/4 2 
297 512/4 1/4 512 32 8/4 4 64 64/4 1 
300 512/4 1/4 512 32 8/4 4 64 64/4 1 
313 256/4 1/4 256 32 4/4 8 64 64/4 1 
326 512/4 1/4 512 32 4/4 8 64 32/4 2 
327 32/4 2/4 16 16 2/4 8 32 16/4 2 
337 256/4 2/4 128 64 4/4 16 32 8/4 4 
338 256/4 1/4 256 32 4/4 8 64 8/4 8 
346 >512/4 32/4 >16 >256 4/4 >64 >512 32/4 >16 
360 >512/4 4/4 >128 128 8/4 16 128 8/4 16 
363 128/4 32/4 4 64 4/4 16 >512 32/4 >16 
381 512/4 2/4 256 64 4/4 16 64 16/4 4 
436 256/4 1/4 256 16 1/4 16 16 8/4 2 
437 512/4 0.5/4 1024 64 8/4 8 32 16/4 2 
489 512/4 1/4 512 32 4/4 8 32 8/4 4 
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Table A6 (continued) 
497 256/4 2/4 128 32 8/4 4 64 32/4 2 
498 >512/4 4/4 >128 128 32/4 4 128 64/4 2 
535 512/4 1/4 512 32 2/4 16 16 16/4 1 
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Table A7: AmpC Expression, OprD Inactivation, and Efflux Pump System Expression and Change in MIC for Each Drug 
Combination Against Each XDR-P. aeruginosa (n=49) (MEM=meropenem; Clox=cloxacillin; IMI=imipenem; Arg=L-arginine; 
PAβN= Phenylalanine-arginine 𝝱-naphthylamide; CFP=cefepime; P=positive; N=negative)† 
Isolate MEM 
& Clox 
MIC 
Change 
AmpC 
-MEM 
IMI & 
Clox 
MIC 
Change 
AmpC 
– IMI 
MEM 
& Arg 
MIC 
Change 
OprD 
– 
MEM 
IMI & 
Arg 
MIC 
Change 
OprD 
– IMI 
MEM 
& 
PAβN 
MIC 
Change  
Efflux 
– 
MEM 
CFP & 
PAβN 
MIC 
Change 
Efflux 
– CFP 
12 2 P 4 P 1 P 2 N 4 P 2 P 
17 1 N 4 P 0.5 N 0.5 N 2 P 2 P 
24 1 N 4 P 1 P 1 P 2 P 2 P 
28 2 P 4 P 0.5 N 0.5 N 2 P 4 P 
29 2 P 4 P 1 P 4 N 2 P 4 P 
36 1 N 2 P 0.25 N 1 P 1 N 0.5 N 
47 1 N 4 P 0.25 N 1 P 1 N 2 P 
61 1 N 4 P 0.5 N 1 P 1 N 1 N 
66 1 N 2 P 1 P 1 P 4 P 4 P 
83 2 P 2 P 1 P 1 P 1 N 1 N 
84 2 P 2 P 0.25 N 1 P 0.5 N 2 P 
85 1 N 2 P 1 P 1 P 1 N 2 P 
88 1 N 1 N 1 P 1 P 1 N 2 P 
92 2 P 2 P 1 P 1 P 2 P 2 P 
93 2 P 2 P 1 P 1 P 1 N 2 P 
96 1 N 4 P 1 P 1 P 2 P 1 N 
107 2 P 4 P 1 P 2 N 2 P 1 N 
115 2 P 2 P 0.5 N 1 P 1 N 1 N 
128 2 P 2 P 0.25 N 1 P 1 N 0.5 N 
131 1 N 2 P 1 P 0.5 N 1 N 2 P 
136 1 N 2 P 0.25 N 0.5 N 1 N 1 N 
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Table A7 (continued) 
144 1 N 4 P 0.5 N 1 P 4 P 2 P 
151 1 N 4 P 0.5 N 1 P 2 P 2 P 
153 1 N 4 P 1 P 1 P 4 P 1 N 
157 1 N 1 N 1 P 1 P >4 P 4 P 
184 1 N 4 P 0.5 N 1 P 4 P 1 N 
208 2 P 2 P 0.5 N 0.5 N 1 N 2 P 
211 2 P 8 P 1 P 1 P 2 P 2 P 
234 1 N 2 P 0.5 N 0.5 N 1 N 1 N 
251 2 P 4 P 1 P 1 P 2 P 2 P 
259 1 N 8 P 1 P 1 P 2 P 2 P 
279 2 P 4 P 1 P 1 P 4 P 1 N 
297 2 P 4 P 1 P 1 P 2 P 1 N 
300 1 N 4 P 0.5 N 1 P 4 P 2 P 
313 1 N 4 P 0.5 N 1 P 2 P 1 N 
326 2 P 4 P 1 P 1 P 2 P 2 P 
327 2 P 8 P 0.5 N 1 P 2 P 4 P 
337 2 P 2 P 1 P 1 P 1 N 1 N 
338 1 N 2 P 0.25 N 1 P 2 P 4 P 
346 1 N 2 P 0.5 N 1 P 2 P 1 N 
360 2 P 4 P 1 P 1 P 2 P 1 N 
363 1 N 2 P 1 P 1 P 2 P 2 P 
381 1 N 2 P 0.25 N 0.5 N 4 P 4 P 
436 2 P 8 P 0.5 N 1 P 2 P 1 N 
437 1 N 4 P 0.5 N 1 P 1 N 2 P 
489 1 N 4 P 0.5 N 1 P 1 N 2 P 
497 1 N 4 P 1 P 1 P 2 P 2 P 
498 2 P 2 P 1 P 1 P 1 N 2 P 
535 2 P 8 P 0.5 N 2 N 2 P 2 P 
†All Changes in MIC = (MIC of Agent Alone) / (MIC of Agent + Inhibitor) 
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Table A8: Phenotypic Expression of Each Mechanism of Resistance by Each XDR-P. aeruginosa Isolate (n=49)  
Isolate KPC MBL AmpC OprD 
Channel 
Efflux System Combination 
12 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
17 Positive Negative Positive Negative Positive AmpC, Efflux 
24 Positive Negative Positive Positive Positive AmpC, OprD, Efflux  
28 Positive Negative Positive Negative Positive AmpC, Efflux 
29 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
36 Positive Negative Positive Positive Negative AmpC, OprD 
47 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
61 Positive Negative Positive Positive Negative AmpC, OprD 
66 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
83 Positive Negative Positive Positive Negative AmpC, OprD 
84 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
85 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
88 Negative Positive Negative Positive Positive MBL, OprD, Efflux 
92 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
93 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
96 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
107 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
115 Positive Negative Positive Positive Negative AmpC, OprD 
128 Positive Negative Positive Positive Negative AmpC, OprD 
131 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
136 Positive Negative Positive Negative Negative AmpC 
144 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
151 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
153 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
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Table A8 (continued) 
157 Positive Negative Negative Positive Positive KPC, OprD, Efflux 
184 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
208 Positive Negative Positive Negative Positive AmpC, Efflux 
211 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
234 Positive Negative Positive Negative Negative AmpC 
251 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
259 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
279 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
297 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
300 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
313 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
326 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
327 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
337 Positive Negative Positive Positive Negative AmpC, OprD 
338 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
346 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
360 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
363 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
381 Positive Negative Positive Negative Positive AmpC, Efflux 
436 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
437 Positive Negative Positive Positive Positive AmpC, OprD, Efflux 
489 Negative Negative Positive Positive Positive AmpC, OprD, Efflux 
497 Positive Positive Positive Positive Positive MBL, AmpC, OprD, Efflux 
498 Positive Positive Positive Positive Positive MBL, AmpC, OprD, Efflux 
535 Positive Negative Positive Negative Positive AmpC, Efflux 
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